ID,LABEL,inSubset,Comment,Parent,alternative label,definition,definition source,term editor,editor note,term tracker item,target receptor,induces immune profile,derives from,equivalent axioms,,,,,
ID,A rdfs:label,A http://www.geneontology.org/formats/oboInOwl#inSubset,,C %,A alternative label SPLIT=|,A definition SPLIT=|,A definition source SPLIT=|,A term editor SPLIT=|,A editor note SPLIT=|,A term tracker item SPLIT=|,C 'target receptor' some % SPLIT=|,C 'induces immune profile' some % SPLIT=|,C 'derives from' some % SPLIT=|,EC %,,,,,
VO:0000093,mineral salt vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that is formed as a mineral salt.,,Samantha G. Sayers|Oliver He,,,,,,,,,,,
VO:0000118,microbial derivative vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that contains microbial derived material.,,Oliver He|Samantha G. Sayers,,,,,,,,,,,
VO:0000127,aluminum hydroxide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum vaccine adjuvant,alum,An aluminum vaccine adjuvant that contains aluminum hydroxide.,,Oliver He,,,,Th2-biased immune profile,,,,,,,
VO:0000128,aluminum phosphate vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum vaccine adjuvant,Adju-Phos®|Al(PO)4,An aluminum vaccine adjuvant that is aluminum phosphate.,,Oliver He|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0000131,calcium phosphate vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,mineral salt vaccine adjuvant,CaHPO4,A mineral salt vaccine adjuvant composed of calcium phosphate.,,Oliver He|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0000133,Freund's emulsified oil adjuvant,vaccine adjuvant,category,emulsion vaccine adjuvant,,"An emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion.",,Oliver He|Samantha G. Sayers,,,,,,,,,,,
VO:0000139,complete Freund's adjuvant,vaccine adjuvant,Vaxjo 1.0,Freund's emulsified oil adjuvant,Freund's Complete Adjuvant,"A Freund's emulsified oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis).",,Oliver He,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0000142,incomplete Freund's adjuvant,vaccine adjuvant,Vaxjo 1.0,Freund's emulsified oil adjuvant,Freund's Incomplete Adjuvant,A Freund's emulsified oil adjuvant that does not contain the mycobacterial components.,,Oliver He,,,,Th2-biased immune profile,,,,,,,
VO:0000143,cholera toxin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,CT|cholera toxin,A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0000146,Corynebacterium-derived P40 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,,A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium.,PMID:8447157,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0000181,lipopolysaccharide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,LPS vaccine adjuvant|LPS,A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0000187,muramyl dipeptide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,MDP|muramyl dipeptide|Muramyl Dipeptide Adjuvant,A synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA).,PMID:344799,Oliver He|Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0000190,squalene vacccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,squalene|Squalene-based Adjuvants,An emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000191,arlacel A vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,arlacel A,A synthetic vaccine adjuvant that is an emulsifier called Arlacel A.,PMID:2042393,Oliver He|Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000192,Montanide 103 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Montanide vaccine adjuvant,Montanide 103,A Montanide vaccine adjuvant that is Montanide 103.,,Oliver He,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000193,Bordetella pertussis component vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,,A microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines.,,Oliver He,,,,Th2/Th17 mixed immune profile ,,,,,,,
VO:0000351,Adjumer vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Adjumer|PCPP salt|polyidi (carboxylatophenoxy) lphosphazene|polyphosphazene,A synthetic vaccine adjuvant that is PCPP salt.,PMID:75551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000366,liposome-based vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,particulate antigen delivery system vaccine adjuvant,Liposomes,"A particulate antigen delivery system vaccine adjuvant that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.",http://www.vaccination.inoz.com/adjuvants.html,Oliver He,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000384,IL-15 plasmid vaccine adjuvant,vaccine adjuvant,AdjuvareDB,IL-15 vaccine adjuvant,,,"PMID:18472194
",Oliver He,,,,Th1-biased immune profile,,,,,,,
VO:0000388,E. coli LT toxin derived vaccine adjuvant,vaccine adjuvant,category,microbial derivative vaccine adjuvant,,A microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT.,PMID:12763689|PMID:29146379|PMID:21135101,Oliver He|Samantha G. Sayers|Josh Monickaraj,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000559,adamantylamide dipeptide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,AdDP,"A synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP.",PMID:8375945,Oliver He|Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0000580,vaccine adjuvant,vaccine adjuvant,category,vaccine component,,A vaccine component is a chemical substance added to a vaccine to enhance and direct the immune response to a protective antigen. Vaccine adjuvants may cause a range of serious side-effects.,,Oliver He|Paola Roncaglia,,https://github.com/vaccineontology/VO/issues/809,,,,('vaccine component' and 'has role' some 'vaccine adjuvant role'),,,,,
VO:0000757,ISCOM vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,particulate antigen delivery system vaccine adjuvant,ISCOM|The immunostimulating complex|ISCOM(s)™,"A particulate antigen delivery system vaccine adjuvant that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.",,Oliver He,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0000884,aluminum vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,mineral salt vaccine adjuvant,,A mineral salt vaccine adjuvant that is composed of some aluminum compound.,,Oliver He,,,,Th2-biased immune profile,,,,,,,
VO:0000938,xanthan gum vaccine ajuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,xanthan gum,"A synthetic vaccine adjuvant that is derived from Xanthomonas campestris, has a pentasaccharide repeating unit structure, and its terminus contains a mannose moiety which acts as a toll-like receptor 2 agonist.",PMID:19608270|http://www.sciencedirect.com/science/article/pii/S0142961209006371,Asiyah Yu Lin,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001147,IL-12 vacince adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,,A cytokine vaccine adjuvant that contains IL-12.,,Oliver He|Allen Xiang,,,,Th1-biased immune profile,,,,,,,
VO:0001237,CpG DNA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,oligonucleotide vaccine adjuvant,,A microbial derivative vaccine adjuvant compsed of CpG DNA.,PMID:12899580,Oliver He,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0001238,Ribi vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,Ribi Vaccine Adjuvant,An emulsion vaccine adjuvant that is a stable oil-in-water emulsion.,http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=M6661%7CSIGMA&N25=0&QS=ON&F=SPEC,Samantha G. Sayers,,,Toll-like receptor 4 | C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0001239,RC529 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,,A synthetic vaccine adjuvant named RC529 that is a lipid A mimetic.,PMID:16204643,Samantha G. Sayers,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001240,aluminum potassium sulfate adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum vaccine adjuvant,,An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2).,,Allen Xiang|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001241,Alhydrogel vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum hydroxide vaccine adjuvant,Alhydrogel,An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions.,PMID:7551218,Allen Xiang|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001242,cholera toxin B subunit vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cholera toxin derived vaccine adjuvant,CTB|cholera toxin B|Cholera toxin B subunit,A cholera toxin derived vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae.,,Samantha G. Sayers,,,,Th2/Th17 mixed immune profile ,,,,,,,
VO:0001249,RC529-AF vaccine adjuvant,vaccine adjuvant,AdjuvareDB,RC529 vaccine adjuvant,RC529 vaccine adjuvant in an aqueour formulation|RC529-AF,An aqueous formula of the synthetic vaccine adjuvant RC529.,PMID: 15308371,,"RC529-AF can be obtained from Corixa Corporation (Seattle, WA).",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001250,monophosphoryl lipid A vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,3-O-deacylated monophosphoryl lipid A vaccine adjuvant|3D-MLA|MPL vaccine adjuvant|MPL,A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595.,PMID:7551218|https://www.frontiersin.org/articles/10.3389/fimmu.2020.577823|PMID:10768940|PMID:28646827,Samantha G. Sayers|Yuping Zheng,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001251,LTK63 vaccine mutant,vaccine adjuvant,Vaxjo 1.0,E. coli LT toxin derived vaccine adjuvant,LTK63 Vaccine Mutant Adjuvant,An E. coli LT toxin derived vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant.,PMID:9607006|PMID:10790422|PMID:17920733,Samantha G. Sayers,LTK63 is an enzymatically inactive mutant of the heat-labile enterotoxin of Escherichia coli. It can be used as a potent mucosal adjuvant.,,,Th2/Th17 mixed immune profile ,,,,,,,
VO:0001259,killed Corynebacterium parvum vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,,A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum.,PMID:5483667|PMID:4596278|PMID:7591056,Samantha G. Sayers,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001260,Titermax Gold vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,Titermax Gold|TiterMax Gold Adjuvant,"An emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate.",,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001261,DDA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Dimethyl dioctadecyl ammonium bromide|DDA Adjuvant,"A synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen.",PMID:1439129,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001262,cationic liposomal vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,liposome-based vaccine adjuvant,Cationic Liposomal Vaccine Adjuvant,A liposome-based vaccine adjuvant that have a positive surface charge.,PMID:19874860,Samantha G. Sayers,,,C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0001263,QuilA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,tensoactive compound vaccine adjuvant,,A tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina.,PMID:7551218,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001264,AS02 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,combination vaccine adjuvant,,"A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.",PMID:15780441|PMID:15187142,Samantha G. Sayers,"monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001265,AS04 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,combination vaccine adjuvant,AS04,A combination vaccine adjuvant that is a combination of 50 ug of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 ug of aluminium salt.,PMID:21527299,Samantha G. Sayers,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001266,VSA-3 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,Emulsigen D|VSA-3|VSA-3 Adjuvant,An emulsion vaccine adjuvant which is an emulsion plus DDA.,PMID:16187717,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001267,saponin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,tensoactive compound vaccine adjuvant,,"A tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega.",,,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001268,Montanide ISA 720 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Montanide vaccine adjuvant,Montanide ISA 720|Montanide ISA 720 VG,A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria.,"PMID:15752840|WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-720-@/view-1044-seproduit.html?menuid=,979,&lang=en",Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001269,Montanide incomplete Seppic adjuvant,vaccine adjuvant,Vaxjo 1.0,Montanide vaccine adjuvant,,A Montanide vaccine adjuvant that is a mineral oil adjuvant.,,,,,,Th1-biased immune profile,,,,,,,
VO:0001270,Montanide ISA51 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,Montanide vaccine adjuvant,Montanide ISA51|Montanide ISA 51,A Montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion.,"WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-51-@/view-1042-seproduit.html?menuid=,979,&lang=en",Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001271,Montanide vaccine adjuvant,vaccine adjuvant,category,emulsion vaccine adjuvant,,An emulsion vaccine adjuvant developed by Montanide.,http://www.montanide.com/,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001272,EtxB vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,E. coli LT toxin derived vaccine adjuvant,B subunit of E. coli heat-labile enterotoxin|Etx B subunit Adjuvant,An E. coli LT toxin derived vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin.,,Oliver He|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001273,Polygen vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,,A synthetic vaccine adjuvant with the tradename Polygen.,URL: http://www.mvp-technologies.com/adjuvants/Polygen%20Final%20Technical%20Bulletin.pdf,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001285,Algal Glucan vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,carbohydrate vaccine adjuvant,Algal Glucan,"A carbohydrate vaccine adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models.",PMID:7551218,Samantha G. Sayers,,,C-type lectin domain family 7 member A,Th1-biased immune profile,,,,,,,
VO:0001286,Algammulin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,combination vaccine adjuvant,Algammulin,A combination vaccine adjuvant that suspension of 1-2um ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens.,PMID:1887671,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001287,BAY R1005 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,BAY R1005|N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate,A synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino beta-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ).,PMID:7551218,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001288,Avridine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,"Avridine|CP20,96|N, N-dioctadecyl-N', N'-bis( 2-hydroxyethyl) propanediamine|Avridine®","A synthetic vaccine adjuvant that is N, N-dioctadecyl-N', N'-bis(2-hydroxyethyl) propanediamine (Avridine).",PMID:7551218,Samantha G. Sayers,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001289,calcium phosphate gel vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,calcium phosphate vaccine adjuvant,calcium phosphate gel,A calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts.,PMID:7551218,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001290,cholera toxin A1-subunit-ProteinA D-fragment fusion protein,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,CTA1-DD gene fusion protein,A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein.,PMID:7551218,Samantha G. Sayers,,,,Th2/Th17 mixed immune profile ,,,,,,,
VO:0001291,DOC/Alum Complex vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,mineral salt vaccine adjuvant,DOC/Alum Complex,A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide.,PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001292,gamma Inulin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,carbohydrate vaccine adjuvant,Gamma Inulin,"A carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose.",PMID:3265692|PMID:7551218,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001293,Gerbu vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,combination vaccine adjuvant,Gerbu Adjuvant,"A combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8).",PMID:7551218|PMID:15953835,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1/Th2 mixed immune profile,,,,,,,
VO:0001294,GM-CSF vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,GM-CSF,A cytokine vaccine adjuvant that includes GM-CSF.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001295,GMDP vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,GMDP|N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine,"A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant.",PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001296,recombinant hIFN-gamma/Interferon-g vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,IFN-gamma vaccine adjuvant,Recombinant hIFN-gamma/Interferon-g,An IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001297,IL-1b vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,interleukin-1b|IL-1b|Interleukin-1β,A cytokine vaccine adjuvant that includes IL-1b.,,Oliver He|Samantha G. Sayers,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0001298,interleukin-2 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,IL-2 vaccine adjuvant|Interleukin-2,A cytokine vaccine adjuvant that includes IL-2.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001299,IL-7 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,IL-7|interleukin-7 vaccine adjuvant|Interleukin-7,A cytokine vaccine adjuvant that includes IL-7 and induces Th1/Th2/Th17 mixed immune profile.,,Oliver He|Samantha G. Sayers|Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0001300,Loxoribine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,7-allyl-8-oxoguanosine|Loxoribine,"A synthetic vaccine adjuvant that includes loxoribine which is a guanosine analog derivatized at position N7 and C8, and activates TLR-7.",PMID:7551218,Samantha G. Sayers,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0001301,MF59 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,MF59,An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion.,PMID:20488726,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001302,MTP-PE Liposomes vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,liposome-based vaccine adjuvant,MTP-PE|MTP-PE Liposomes,"A liposome-based vaccine adjuvant that consists of liposomes containing  the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE).",PMID:1431559,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001303,Murametide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Murametide|Nac-Mur-L-Ala-D-Gln-OCH3,A synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP.,PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001304,Murapalmitine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Murapalmitine|Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl|L-Murapalmitine,A synthetic vaccine adjuvant called murapalmitine.,PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001305,D-Murapalmitine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,D-Murapalmitine|Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl,A synthetic vaccine adjuvant that includes an MDP analog called D-Murapalmitine.,PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001306,NAGO vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,NAGO|Neuraminidase-galactose oxidase,A synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase.,PMID:7551218,Samantha G. Sayers,,,,,,,,,,,
VO:0001307,non-ionic surfactant vesicles vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,NISV|non-ionic surfactant vesicles,"A synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen.",PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001308,PMMA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,PMMA|Polymethyl methacrylate,A synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate.,PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001309,protein cochleates vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,protein cochleates,A synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates.,PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001310,QS-21 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,saponin vaccine adjuvant,QS-21|Stimulon™ QS-21 Adjuvant,"A saponin vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. Specifically, it is an acylated 3, 28-bisdesmodic triterpene glycosides (1,3) or ""saponin""  with a molecular formula of C92O46H148 and molecular weight of 1990 Da. QS-21 is one of the active fractions of the bark of Chilean tree, Quillaja saponaria, purified using a reverse-phase chromatography (RP-HPLC).",PMID:7551218|PMID:27213168,Samantha G. Sayers|Randi Vita|Oliver He,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001311,Rehydragel HPA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum vaccine adjuvant,Rehydragel HPA,An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation.,PMID:7551218,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001312,Rehydragel LV vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum hydroxide vaccine adjuvant,Rehydragel LV,An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel.,PMID:7551218,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001313,Sclavo peptide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,IL-1β 163-171 peptide vaccine adjuvant|Sclavo peptide,A cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001314,Specol vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,Specol,An emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA).,PMID:1439130,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001315,SPT (Antigen Formulation) vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,SPT (Antigen Formulation),"An emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen.",PMID:7551218,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001316,stearyl tyrosine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,stearyl tyrosine,"A synthetic vaccine adjuvant stearyl tyrosine is considered an ""organic equivelant"" of aluminum hydroxide.",PMID:7551218,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001317,Theramide vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Theramide|Theramide®,A synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP).,PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001318,CRL1005 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,CRL1005,"A synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE.",PMID:10717336,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001319,nanoemulsion vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,,An emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA.,http://nano.med.umich.edu/platforms/Nanoemulsions.html,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001320,AS03 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,AS03,"An emusion vaccine adjuvant that contains alpha-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion.",PMID:21256188,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001321,LTR192G vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,E. coli LT toxin derived vaccine adjuvant,LTR192G|LT(R192G),An E. coli LT toxin derived vaccine adjuvant that is a mutant form of E.coli heat-labile toxin.,PMID:11803061|PMID:32978003,Samantha G. Sayers|Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0001322,E. coli heat-labile toxin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,"E. coli heat-labile toxin, LT|LT Oral Adjuvant|LT-OA",A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin.,PMID:7551218,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001323,amorphous aluminum hydroxyphosphate sulfate adjuvant,vaccine adjuvant,Vaxjo 1.0,aluminum vaccine adjuvant,AAHSA|Merck Aluminum Adjuvant|AAHS,An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants.,PMID:17581283|PMID:32763959,Samantha G. Sayers|Le Liu,,,,Th2-biased immune profile,,,,,,,
VO:0001324,Matrix-S vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,tensoactive compound vaccine adjuvant,Matrix-S,,,,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001328,imiquimod vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,"1-(2-methypropyl)-IH-imidazo[4,5-c]quinolin-4-amine|Aldara™|R-837|S26308|Imiquimod",A synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline.,PMID:7551218|PMID:18566444,Samantha G. Sayers,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0001329,resiquimod vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,Resiquimod,"A synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod.",PMID:15068862,Samantha G. Sayers,,,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0001330,AF03 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,emulsion vaccine adjuvant,AF03,An emulsion vaccine adjuvant containing 2.5% squalene.,PMID:20193791,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001331,Flagellin vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,Flagellin protein,Microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria.,PMID:16428759|PMID:21048152,Samantha G. Sayers,,,Toll-like receptor 5,Th1-biased immune profile,,,,,,,
VO:0001332,poly(I:C) vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,polyriboinosinic-polyribocytidylic acid|Polyinosinic-polycytidylic acid,"A synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA.",WEB: http://en.wikipedia.org/wiki/Polyinosinic:polycytidylic_acid|PMID:30079840|PMID:27622060,Samantha G. Sayers|Taiyu Lin|Yuping Zheng,,,Toll-like receptor 3 | antiviral innate immune response receptor RIG-I,Th1-biased immune profile,,,,,,,
VO:0001333,ISCOMATRIX vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,particulate antigen delivery system vaccine adjuvant,ISCOMATRIX®,"A particulate antigen delivery system vaccine adjuvant that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.",PMID:19450632,Samantha G. Sayers,ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431.,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001334,Abisco-100 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,saponin vaccine adjuvant,,A saponin vaccine adjuvant that is made from highly purified saponins.,WEB: http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx,Samantha G. Sayers|Oliver He,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001335,albumin-heparin microparticles vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,particulate antigen delivery system vaccine adjuvant,,A particulate antigen delivery system vaccine adjuvant  that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.,PMID:16734558,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001337,B7-2 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,,A cytokine vaccine adjuvant that includes B7-2.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001338,Bupivacaine vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,,"A synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines.",PMID:15246629|WEB: http://en.wikipedia.org/wiki/Bupivacaine,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001339,cationic liposome-DNA complex JVRS-100 vaccin adjuvant,vaccine adjuvant,Vaxjo 1.0,liposome-based vaccine adjuvant,cationic liposome-DNA complex JVRS-100,A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid.,PMID:19285425,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001340,DHEA vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,5-androsten-3β-ol-17-one|DHA|Dehydroepiandrosterone|androstenolone|prasterone|transdehydroandrosterone,"A synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations.",PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001341,DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,PLGA|PLGA microspheres|Polyester poly (DL-lactide-co-glycolide),"A synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs.",PMID:15560948,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001342,IL-15 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cytokine vaccine adjuvant,IL-15,A cytokine vaccine adjuvant that uses the adjuvant effect of cytokine IL-15.,PMID:27001957,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001343,immunoliposomes vaccine adjuvant containing antibodies to costimulatory molecules,vaccine adjuvant,Vaxjo 1.0,liposome-based vaccine adjuvant,Immunoliposomes Containing Antibodies to Costimulatory Molecules,A liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs).,PMID:7551218,Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0001344,LTR72 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,E. coli LT toxin derived vaccine adjuvant,,An E. coli LT toxin derived vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala -> Arg  in position 72 of the A subunit.,PMID:9529328,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001345,MPL-SE vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,,A microbial derivative vaccine adjuvant containing MPL and squalene.,PMID:12213399,Samantha G. Sayers,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0001347,non-toxic mutant E112K of Cholera Toxin mCT-E112K vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cholera toxin derived vaccine adjuvant,mCT|non-toxic mutant E112K of Cholera Toxin mCT-E112K,"A microbial derived vaccine adjuvant made of E112K mC,  a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112.",PMID:11251876,Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001348,cholera toxin derived vaccine adjuvant,vaccine adjuvant,category,microbial derivative vaccine adjuvant,,A microbial derivative vaccine adjuvant that is derived from cholera toxin.,,Oliver He|Samantha G. Sayers,,,,Th2-biased immune profile,,,,,,,
VO:0001349,SAF-1 vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,combination vaccine adjuvant,SAF-1,"A combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic(R) L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)].",PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1/Th2 mixed immune profile,,,,,,,
VO:0001350,"Sendai Proteoliposomes, Sendai-containing Lipid Matrices vaccine adjuvant",vaccine adjuvant,Vaxjo 1.0,liposome-based vaccine adjuvant,"Sendai Proteoliposomes, Sendai-containing Lipid Matrices",A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus.,PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001351,threonyl muramyl dipeptide (TMDP) vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,synthetic vaccine adjuvant,N-acetyl muramyl-L-threonyl-D-isoglutamine|Termurtide™|[thr1 ]-MDP,A synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP).,PMID:7551218,Samantha G. Sayers,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0001352,ty particles vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,microbial derivative vaccine adjuvant,Ty-VLPs,A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded.,PMID:7551218,Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001353,cytokine vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that contains active cytokine compound.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2/Th17/Tfh mixed immune profile,,,,,,,
VO:0001354,combination vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that is composed of differnt compounds under more than one category.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0001355,emulsion vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,,,,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001356,particulate antigen delivery system vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that serves as a particulate antigen delivery system.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001357,synthetic vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that contains synthetic material.,,Oliver He|Samantha G. Sayers|Philip Huang,,,,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0001358,tensoactive compound vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,tensioactive compound vaccine adjuvant,"A vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface.",WEB: http://www.citt.ufl.edu/team/sepulveda/html/en_tensioactivos.htm,Oliver He|Samantha G. Sayers,,,,Th1/Th2/Tfh mixed immune profile,,,,,,,
VO:0001359,carbohydrate vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that is primarily composed of carbohydrates.,,Oliver He|Samantha G. Sayers,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0001360,IFN-gamma vaccine adjuvant,vaccine adjuvant,category,cytokine vaccine adjuvant,,A cytokine vaccine adjuvant that includes IFN-gamma.,,Oliver He|Samantha G. Sayers,,,,Th1-biased immune profile,,,,,,,
VO:0005206,Matrix-M vaccine adjuvant,vaccine adjuvant,AdjuvareDB,saponin vaccine adjuvant,Matrix-M,"A saponin vaccine adjuvant comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid.",PMID:22844480,Philip Huang,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005207,Advax vaccine adjuvant,vaccine adjuvant,VAC,carbohydrate vaccine adjuvant,Advax|delta-inulin,A carbohydrate vaccine adjuvant derived from delta inulin,PMID:22728225|PMID:33542494|https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000|https://www.ncbi.nlm.nih.gov/pubmed/?term=12|https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440|https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134|https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758|https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215|https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913|https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330|https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225|https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367|https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724|https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620|https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245|https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701|https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153|https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531|https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480|https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500|https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269|https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451|https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480|https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344|https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914|https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280|https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608|https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380|https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637|https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687|https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742|https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015|https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356|https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889|https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280|https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494|https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559,Nikolai Petrovsky|Wolfgang Leitner|Philip Huang|Oliver He|Le Liu,"Chemical Nature: Carbohydrate
Mechanism of Action: Complement, Dendritic cells (unknown receptor), Other, Unknown
Immune profile induced: mixed Th1/Th2
By routes: IM, IN, IP, SQ, inhalation,
Point of Contact: Nikolai Petrovsky, Vaxine
https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889
https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500
https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637
https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620
https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245
https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367
https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758
https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440
https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451
https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269
https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559
https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742
https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913
https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687
https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531
https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701
https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480
https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134
https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724
https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215
https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356
https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015
https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608
https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380
https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494
https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344
https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225
https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225
https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153
https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280
https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280
https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330
https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480
https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000
https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914
https://www.ncbi.nlm.nih.gov/pubmed/?term=12",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005270,1V270 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,1V270,"A vaccine adjuvant that includes IV270, which is a low-molecular weight TLR7 agonist conjugated to a phospholipid and is a highly potent and stable immune activator.",PMID:25568203|PMID:28724768|PMID:32636840/,Dennis Carson|Wolfgang Leitner|Oliver He,"Chemical Nature: Small molecule
Receptor: TLR7
Mechanism of Action: Activation of innate immune pathways
Immune profile induced: Th1-biased
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody affinity maturation, (6) Promotes antibody epitope spreading By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005271,2B182C vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,2B182C,,https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203|https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Anti-inflammatory, (3) Promotes antibody epitope spreading. By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005281,2E151 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,2E151,,,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: Dendritic cells (unknown receptor)
Mechanism of Action: Innate immune activation
Immune profile induced: Th1-biased
Other Features/Characteristics: Other. Specify: Co-adjuvant for TLR4 ligands
Point of Contact: Dennis Carson, UCSD",,,Th1-biased immune profile,,,,,,,
VO:0005282,UM-1098 vaccine adjuvant,vaccine adjuvant,VAC,particulate antigen delivery system vaccine adjuvant,UM-1098,,,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: CLR (Dectin, Mincle)
Mechanism of Action: None/Unknown
Immune profile induced: Th17-component
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,,Th17-biased immune profile,,,,,,,
VO:0005283,TQL-1055 vaccine adjuvant,vaccine adjuvant,VAC,saponin vaccine adjuvant,TQL-1055,,,Melissa Malhame|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule and Synthetic derivative of natural compound
Receptor: Unknown and NLRP3
Mechanism of Action: Presumably the same as QS-21 in the absence of dose-limiting toxicity
Immune profile induced: Th1-biased
Other Features/Characteristics: None
Point of Contact: Melissa Malhame, Adjuvance Technologies",,,Th1-biased immune profile,,,,,,,
VO:0005284,NanoVax/NE01 vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,NanoVax/NE01,,https://www.ncbi.nlm.nih.gov/pubmed/?term=31495593|https://www.ncbi.nlm.nih.gov/pubmed/?term=31515143,Ali Fattom|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Emulsion
Receptor: TLR2 and TLR4
Mechanism of Action: Activation of mucosal and systemic immunity
Immune profile induced: Th1/Th17
Other Features/Characteristics: Promotes antibody affinity maturation
Point of Contact: Ali Fattom, BlueWillow Biologics",,Toll-like receptor 2 | Toll-like receptor 4,Th1/Th17 mixed immune profile,,,,,,,
VO:0005285,MiT4 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,MiT4,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Other
Receptor: TLR4
Mechanism of Action: TLR4 agonist
Immune profile induced: Th1-biased
Other Features/Characteristics: None/Unknown
Point of Contact: Darrick Carter, PAI Life Sciences",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005286,Mannadjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,,,,Ivan Zanoni|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: (1) Natural compound, (2) Carbohydrate, (3) Combination adjuvant
Receptor: CLR (Dectin, Mincle) and NAIP
Mechanism of Action: Activation of Dectin-2-expressing innate immune cells; dual targeting of injection site and draining lymph node.
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: Promotes antibody epitope spreading
Point of Contact: Ivan Zanoni, Boston Children's Hospital",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005287,LiT4 vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,LiT4,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Combination Adjuvant
Receptor: TLR4
Mechanism of Action: TLR4 agonist plus potential inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None/Unknown
Point of Contact: Darrick Carter, PAI Life Sciences",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005288,INI-4001 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,INI-4001,,,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: TLR7 and TLR8
Mechanism of Action: None/Unknown
Immune profile induced: Th1-biased
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005289,INI-2004 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,INI-2004,,,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: None/Unknown
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005290,INI-2002 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,INI-2002,,,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: None/Unknown
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005291,Fos47 vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,Fos47,,https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203|https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule and Combination adjuvant
Receptor: TLR4 and TLR7
Mechanism of Action: Activation of antigen presenting cells and stimulating B cell proliferation
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody epitope spreading. By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",,Toll-like receptor 4 | Toll-like receptor 7,Th1/Th2 mixed immune profile,,,,,,,
VO:0005292,EmT4 vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,EmT4,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Emulsion
Receptor: TLR4
Mechanism of Action: Squalene emulsion plus TLR4
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Sciences",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005293,Em vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,Em,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Emulsion
Receptor: Unknown
Mechanism of Action: Squalene emulsion possibly triggering inflammasome or through extracellular ATP
Immune profile induced: None
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Sciences",,,,,,,,,,
VO:0005294,defective viral genome-derived oligonucleotide vaccine adjuvant,vaccine adjuvant,VAC,oligonucleotide vaccine adjuvant,DDO|DDO (Defective viral genome-Derived Oligonucleotide)|Defective viral genome-Derived Oligonucleotide,,https://www.ncbi.nlm.nih.gov/pubmed/?term=24099876|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861183,Carolina Lopez|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) Nucleic acid
Receptor: TLR3
Mechanism of Action: TLR3, possibly RIG-I - agonist
Immune profile induced: Th1-biased
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection. By routes: SQ, IM.
Point of Contact: Carolina Lopez, University of Washington at St Louis",,Toll-like receptor 3 | interferon-induced helicase C domain-containing protein 1 | antiviral innate immune response receptor RIG-I,Th1-biased immune profile,,,,,,,
VO:0005295,CaPNP (CaPtivant)(TM) vaccine adjuvant,vaccine adjuvant,VAC,mineral salt vaccine adjuvant,CaPNP (CaPtivant)(TM),,https://www.ncbi.nlm.nih.gov/pubmed/?term=11063495|https://www.ncbi.nlm.nih.gov/pubmed/?term=12204953|https://www.ncbi.nlm.nih.gov/pubmed/?term=28716554|https://www.ncbi.nlm.nih.gov/pubmed/?term=28933657|https://www.ncbi.nlm.nih.gov/pubmed/?term=31591662,Tulin Morcol|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Synthetic derivative of natural compound
Receptor: Unknown
Mechanism of Action: (1) Antigen carrier, (2) Innate immune enhancer/activator
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection, (4) Other, (5) Promotes antibody affinity maturation, (6) High stability. By routes: IM, IN, IP, IN, ID, IVag. Specify: Safe for systemic or mucosal administration
Point of Contact: Tulin Morcol, Captivate Pharma",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005296,BECC470b vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,BECC470b,,https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179|https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule, other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: Other
Point of Contact: Robert Ernst, University of Maryland - Baltimore",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005297,BECC438s vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,BECC438s,,,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Robert Ernst, University of Maryland-Baltimore",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005298,BECC438b vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,BECC438b,,https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179|https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule, other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Robert Ernst, University of Maryland Baltimore",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005299,AlT4 vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,AlT4,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Combination adjuvant
Receptor: TLR4
Mechanism of Action: TLR4 and potentially inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Services",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005300,AlT3 vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,AlT3,,,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Combination adjuvant
Receptor: TLR3
Mechanism of Action: TLR3 agonist plus potential inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Services",,Toll-like receptor 3,Th1/Th2 mixed immune profile,,,,,,,
VO:0005301,Alhydroxiquim-II vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,Alhydroxiquim-II,,https://www.ncbi.nlm.nih.gov/pubmed/?term=33521604|https://www.ncbi.nlm.nih.gov/pubmed/?term=33654090,Sunil David|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: (1) TLR7, (2) TLR8
Mechanism of Action: TLR7/8 dual agonist - lymph node delivery
Immune profile induced: Th1-biased
Other Features/Characteristics: Promotes antibody affinity maturation
Point of Contact: Sunil David, Virovax",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005302,Adjuplex+GLA vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,Adjuplex+GLA,,https://www.ncbi.nlm.nih.gov/pubmed/?term=32984856|https://www.ncbi.nlm.nih.gov/pubmed/?term=33444400|https://www.ncbi.nlm.nih.gov/pubmed/?term=33767689,Marulasiddappa Suresh|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) Emulsion, (3) Combination adjuvant, (4) Other
Receptor: TLR4
Mechanism of Action: Adjuplex enhances cross presentation to CD8 T cells and GLA stimulates TLR4 signaling
Immune profile induced: Mixed Th1/Th17
Other Features/Characteristics: None
Point of Contact: Marulasiddappa Suresh, UW Madison",,Toll-like receptor 4,Th1/Th17 mixed immune profile,,,,,,,
VO:0005303,2F52 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,2F52,,https://www.ncbi.nlm.nih.gov/pubmed/?term=29751735,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,"Chemical Nature: Small molecule
Receptor: Dendritic cells (unknown receptor)
Mechanism of Action: Innate immune activation/enhancer
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Dennis Carson, UCSD",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005324,Advax-CpG55.2 vaccine adjuvant,vaccine adjuvant,VAC,Advax-CpG vaccine adjuvant,Advax-CpG55.2,An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2.,https://pubmed.ncbi.nlm.nih.gov/32636840/|https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580|https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575,Nikolai Petrovsky|Wolfgang Leitner|Oliver He,"Pubmed References:Chemical Nature: (1) combination adjuvant
Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1
Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability
By routes: SQ, IM
Point of Contact: Nikolai Petrovsky, Vaxine LTD",,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005325,VSA-2 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,VSA-2,A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step.  VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21.  VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable sources.,https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001,Pengfei Wang|Wolfgang Leitner|Oliver He,"Pubmed References:
Chemical Nature: (1) Synthetic derivative of natural compound
Mechanism of Action: unknown
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21
By routes: SQ
Point of Contact: Pengfei Wang, University of Alabama
https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005326,VSA-1 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,VSA-1,A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available.,https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920,Pengfei Wang|Wolfgang Leitner|Oliver He,"Pubmed References:
Chemical Nature: (1) Synthetic derivative of natural compound
Mechanism of Action: unknown
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21
By routes: SQ
Point of Contact: Pengfei Wang, University of Alabama
https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005327,rOv-ASP-1 vaccine adjuvant,vaccine adjuvant,VAC,microbial derivative vaccine adjuvant,Recombinant O. volvulus activation-associated secreted protein-1|rOv-ASP-1,"A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1.",https://www.ncbi.nlm.nih.gov/pubmed/?term=1583768|https://www.ncbi.nlm.nih.gov/pubmed/?term=18341617|https://www.ncbi.nlm.nih.gov/pubmed/?term=18675867|https://www.ncbi.nlm.nih.gov/pubmed/?term=22615877|https://www.ncbi.nlm.nih.gov/pubmed/?term=24681229|https://www.ncbi.nlm.nih.gov/pubmed/?term=25736195|https://www.ncbi.nlm.nih.gov/pubmed/?term=26795365|https://www.ncbi.nlm.nih.gov/pubmed/?term=29764680|https://www.ncbi.nlm.nih.gov/pubmed/?term=32471056,Sara Lustigman|Wolfgang Leitner|Oliver He,"Pubmed References:
Chemical Nature: (1) Protein
Mechanism of Action: unknown
Immune profile induced: Th1
Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation.
By routes: IM
Point of Contact: Sara Lustigman, New York Blood Center",,,Th1-biased immune profile,,,,,,,
VO:0005329,dmLT vaccine adjuvant,vaccine adjuvant,VAC,E. coli LT toxin derived vaccine adjuvant,dmLT|dmLT (double mutant of heat-labile E.coli)|double mutant of heat-labile E.coli,A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A),https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067|https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994|https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122|https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621|https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241|https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827|https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825|https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536|https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793|https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197|https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125|https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082|https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441|https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379|https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349,Elizabeth Norton|Wolfgang Leitner|Oliver He,"Chemical Nature: protein
Mechanism of Action: CGM1 ganglioside, cAMP, inflammasome
Immune profile induced: mixed Th1/Th17
Other Features/Characteristics: Induces mucosal immunity (IM, ID, SQ, SL, oral, , transcutaneous), Induces epitope spreading, Promotes antibody affinity maturation, Effective in newborns, promotes antibody epitope spreading
By routes: IM, ID, SL, oral, SQ, IN, IP, intragastric, transcutaneous, transdermal, buccal, intrarectal
Point of Contact: Elizabeth Norton, Tulane University

https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994
https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349
https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197
https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082
https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793
https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827
https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241
https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122
https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825
https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621
https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536
https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379
https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125
https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441
https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067
https://www.ncbi.nlm.nih.gov/pubmed/?term=25944298
https://www.ncbi.nlm.nih.gov/pubmed/?term=6424635
https://www.ncbi.nlm.nih.gov/pubmed/?term=3916310
https://www.ncbi.nlm.nih.gov/pubmed/?term=4826740
https://www.ncbi.nlm.nih.gov/pubmed/?term=2884428
https://www.ncbi.nlm.nih.gov/pubmed/?term=30778066
https://www.ncbi.nlm.nih.gov/pubmed/?term=4893257
https://www.ncbi.nlm.nih.gov/pubmed/?term=28063704
https://www.ncbi.nlm.nih.gov/pubmed/?term=4375349
https://www.ncbi.nlm.nih.gov/pubmed/?term=28792004
https://www.ncbi.nlm.nih.gov/pubmed/?term=25765967
https://www.ncbi.nlm.nih.gov/pubmed/?term=25483682
https://www.ncbi.nlm.nih.gov/pubmed/?term=30638799
https://www.ncbi.nlm.nih.gov/pubmed/?term=21326197
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=31427449
https://www.ncbi.nlm.nih.gov/pubmed/?term=6957164
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=31641151
https://www.ncbi.nlm.nih.gov/pubmed/?term=27133878
https://www.ncbi.nlm.nih.gov/pubmed/?term=27676456
https://www.ncbi.nlm.nih.gov/pubmed/?term=27226279
https://www.ncbi.nlm.nih.gov/pubmed/?term=22406456
https://www.ncbi.nlm.nih.gov/pubmed/?term=30787109
https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527
https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527
https://www.ncbi.nlm.nih.gov/pubmed/?term=30563789
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=30473185
https://www.ncbi.nlm.nih.gov/pubmed/?term=30248001
https://www.ncbi.nlm.nih.gov/pubmed/?term=24049109
https://www.ncbi.nlm.nih.gov/pubmed/?term=30797634
https://www.ncbi.nlm.nih.gov/pubmed/?term=31482013
https://www.ncbi.nlm.nih.gov/pubmed/?term=29771685
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=25444830

Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03922061
https://clinicaltrials.gov/ct2/show/NCT04232943
https://clinicaltrials.gov/ct2/show/NCT02531685
https://clinicaltrials.gov/ct2/show/NCT02052934
https://clinicaltrials.gov/ct2/show/NCT02531802
https://clinicaltrials.gov/ct2/show/NCT01147445
https://clinicaltrials.gov/ct2/show/NCT03548064
https://clinicaltrials.gov/ct2/show/ NCT01739231
https://clinicaltrials.gov/ct2/show/NCT03404674
https://clinicaltrials.gov/ct2/show/NCT03729219
https://clinicaltrials.gov/ct2/show/NCT04826094",,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005330,CPDI-01 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,CPDI-01,,https://pubmed.ncbi.nlm.nih.gov/10516626/|https://pubmed.ncbi.nlm.nih.gov/10799917/|https://pubmed.ncbi.nlm.nih.gov/12538044/|https://pubmed.ncbi.nlm.nih.gov/19428909/|https://pubmed.ncbi.nlm.nih.gov/21723901/|https://pubmed.ncbi.nlm.nih.gov/9013982/,Joseph Vetro|Wolfgang Leitner|Oliver He,"Chemical Nature: (1) other (Peptide)
Mechanism of Action: C5aR1 on mononuclear phagocytes
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation.
By routes: SQ, IP, IV.
Point of Contact: Joseph Vetro, University of Nebraska Medical Center
https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/10516626/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/12538044/, https://pubmed.ncbi.nlm.nih.gov/19428909/, https://pubmed.ncbi.nlm.nih.gov/21723901/",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005337,UM-3005 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,UM-3005,"A vaccine adjuvant that includes UM-3005, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, InImmune",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005353,UM-3004 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,UM-3004,"A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005354,UM-3003 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,UM-3003,"A vaccine adjuvant that includes UM-3003, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005355,LTA1 vaccine adjuvant,vaccine adjuvant,VAC,E. coli LT toxin derived vaccine adjuvant,LTA1,"A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC). This LTA1 adjuvant is able to induce Th1, Th2, and Th17 immune responses.",https://www.ncbi.nlm.nih.gov/pubmed/22526674|https://www.ncbi.nlm.nih.gov/pubmed/26305793|https://www.ncbi.nlm.nih.gov/pubmed/31427449|https://www.ncbi.nlm.nih.gov/pubmed/31641151|https://www.ncbi.nlm.nih.gov/pubmed/31929548|https://www.ncbi.nlm.nih.gov/pubmed/33986280|https://www.ncbi.nlm.nih.gov/pubmed/34516780|https://www.ncbi.nlm.nih.gov/pubmed/6957164,Elizabeth Norton|Wolfgang Leitner|Oliver He|Ani M. Bernardi,"Chemical Nature: (1) Protein
Mechanism of Action: cAMP, inflammasome induction
Immune profile induced: mixed Th1/Th2/Th17
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces epitope spreading, (3) Promotes antibody affinity maturation, (4) Promotes antibody epitope spreading, (5) High stability
Route of immunization: IM, IN, SL, ID, IP
Point of Contact: Elizabeth Norton, Tulane University",,,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0005356,Adjuvax vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Adjuvax,A carbohydrate vaccine adjuvant that is a glucan carbohydrate microcapsules with a beta(1-3)/beta(1-6) - linked glucan structure to allow targeting of antigens to macrophages or neutrophils through interactions with the beta-glucan receptor found uniquely on the surface of these cell types. Adjuvax- ligand complexes are formed by physically entrapping or crosslinking the ligand within the beta-glucan.,DOI: 10.1021,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005357,Advax-CpG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,Advax-2|Advax-SM|Advax-CpG,A vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide (ODN).,https://pubmed.ncbi.nlm.nih.gov/32636840/|https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580|https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575,Nikolai Petrovsky|Wolfgang Leitner|Oliver He,"Pubmed References:Chemical Nature: (1) combination adjuvant
Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1
Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability
By routes: SQ, IM
Point of Contact: Nikolai Petrovsky, Vaxine LTD",,,Th1-biased immune profile,,,,,,,
VO:0005358,AS01B vaccine adjuvant,vaccine adjuvant,AdjuvareDB,AS01 vaccine adjuvant,AS01B,"A combination vaccine adjuvant includes 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution.","https://www.fda.gov/media/107538/download#:~:text=The%20AS01B%20adjuvant%20suspension%20is,DOPC)%20and%20cholesterol%20in%20phosphate%2D",Randi Vita|Oliver He,,,Toll-like receptor 4,,,,,,,,
VO:0005359,AS02A vaccine adjuvant,vaccine adjuvant,AdjuvareDB,AS02 vaccine adjuvant,AS02A,"An AS02 vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL.",https://clinicaltrials.gov/ct2/show/NCT00308061,,,,Toll-like receptor 4,,,,,,,,
VO:0005360,chitosan vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Chitosan,A carbohydrate vaccine adjuvant that is aminoglycan consisting of beta-(1->4)-linked D-glucosamine residues and induces Th1/Th17 mixed immune profile.,CHEBI:16261|PMID:24346613|PMID:34973993,Randi Vita|Oliver He|Le Liu,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005361,Montanide IMS 1313 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Montanide vaccine adjuvant,IMS 1313 N VGPR|IMS-1313|Montanide IMS 1313,A Montanide vaccine adjuvant that is a water-dispersed liquid IMS 1313 nanoparticle combined with an immuno-stimulating compound.,https://scialert.net/abstract/?doi=ijps.2018.167.174,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005362,Montanide ISA 206 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Montanide vaccine adjuvant,ISA-206|Montanide ISA 206,A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound.,PMID:8961504,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005363,Montanide ISA 50 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Montanide vaccine adjuvant,ISA-50|Montanide ISA 50,"A Montanide vaccine adjuvant that Mannide oleate derivative in a mineral oil solution ( Seppic SA, France).",http://vetarhiv.vef.unizg.hr/papers/74-2/raman.pdf,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005364,Tomatine vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Tomatine,"A carbohydrate vaccine adjuvant that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose.",CHEBI:9630,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005365,Zymosan vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Zymosan,A carbohydrate vaccine adjuvant that polysaccharide prepared from the cell wall of Saccaromyces cerevisiae (bakers' yeast).,PMID:11380697,Randi Vita|Oliver He,,,C-type lectin domain family 7 member A,,,,,,,,
VO:0005366,XtendIII vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,XtendIII,"An emulsion vaccine adjuvant that is oil-based adjuvant (Adjuvant XtendIII®; Grand Laboratories, Larchwood, IA).",,Randi Vita|Oliver He,,,,,,,,,,,
VO:0005367,MPL + TDM vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Monophosphoryl-lipid A + Trehalose dicorynomycolate|MPL + TDM,A microbial derivative vaccine adjuvant that is monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) in 2% oil (squalene)-Tween 80-water.,https://www.sigmaaldrich.com/US/en/product/sigma/m6536,Randi Vita|Oliver He,,,Toll-like receptor 4 | C-type lectin domain family 4 member E,,,,,,,,
VO:0005368,Syntex Adjuvant Formulation,vaccine adjuvant,AdjuvareDB,muramyl dipeptide vaccine adjuvant,SAF,A muramyl dipeptide vaccine adjuvant that muramyl dipeptide derivative (threonyl-MDP) in an oil-in-water (o/w) emulsion vehicle.,https://link.springer.com/protocol/10.1385/1-59259-083-7:229,Randi Vita|Oliver He,,,nucleotide-binding oligomerization domain-containing protein 2,,,,,,,,
VO:0005369,dibutyl phthalate vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,DBP|dibutyl phthalate,A vaccine adjuvant that diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol.,CHEBI:34687|PMID:26319029,Randi Vita|Oliver He,,,,Th17-biased immune profile,,,,,,,
VO:0005370,glycerol vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,"glycerine, 1, 2, 3-propanetriol|glycerol",A vaccine adjuvant that includes naturally occurring trivalent alcohol.,https://academic.oup.com/cid/article/45/10/1277/277413,Randi Vita|Oliver He,,,,Th17-biased immune profile,,,,,,,
VO:0005371,Pam3Cys vaccine adjuvant,vaccine adjuvant,AdjuvareDB,TLR agonist vaccine adjuvant,Tripalmitoyl-S-glyceryl-cysteine|Pam3Cys,A vaccine adjuvant includes three palmitic acid groups that are bound in an ester and amide linkage to a cysteine residue.,PMID:24130558,Randi Vita|Oliver He,,,Toll-like receptor 1 | Toll-like receptor 2,Th17-biased immune profile,,,,,,,
VO:0005372,Vaxfectin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,liposome-based vaccine adjuvant,Vaxfectin,"A vaccine adjuvant that is equimolar mixture of the cationic lipid GAP-DMORIE [(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide)] and a neutral colipid DPyPE (1,2-diphytanoyl-sn-glydero-3-phosphoethanolamine).",PMID:21118032,Randi Vita|Oliver He,,,,Th17-biased immune profile,,,,,,,
VO:0005375,T-vant vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,T-vant,"A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation.",https://www.ncbi.nlm.nih.gov/pubmed/?term=33498352|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069796,Lisa Morici|Wolfgang Leitner|Oliver He,"Chemical Nature: other
Mechanism of Action: TLR4; inflammasome; DC activation
Immune profile induced: Th1/Th2/Th17
Receptor: TLR4, NLRP3
Storage information: -20 or -80C
Point of Contact: Lisa Morici, Tulane University",,Toll-like receptor 4,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0005379,PIKA vaccine adjuvant,vaccine adjuvant,VAC,nucleic acid vaccine adjuvant,PIKA,,https://www.ncbi.nlm.nih.gov/pubmed/?term=17484805|https://www.ncbi.nlm.nih.gov/pubmed/?term=20538850|https://www.ncbi.nlm.nih.gov/pubmed/?term=21468931|https://www.ncbi.nlm.nih.gov/pubmed/?term=26765968|https://www.ncbi.nlm.nih.gov/pubmed/?term=28118938|https://www.ncbi.nlm.nih.gov/pubmed/?term=29174316|https://www.ncbi.nlm.nih.gov/pubmed/?term=34766005,Xiaoliang Ren|Wolfgang Leitner|Oliver He,"Chemical Nature: Nucleic Acid
Mechanism of Action: TLR/RLR-agonist
Immune profile induced: Th1/Th2

Route of immunization: IM and IN
Point of Contact: Xiaoliang Ren, Yisheng Bio

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02657161
https://clinicaltrials.gov/ct2/show/NCT02956421",,Toll-like receptor 3 | interferon-induced helicase C domain-containing protein 1 | antiviral innate immune response receptor RIG-I,Th1/Th2 mixed immune profile,,,,,,,
VO:0005380,Mastoparan 7 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,Mastoparan 7,,https://www.ncbi.nlm.nih.gov/pubmed/?term=31068425|https://www.ncbi.nlm.nih.gov/pubmed/?term=32047657|https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991,Herman Staats|Wolfgang Leitner|Oliver He,"Chemical Nature: peptide
Mechanism of Action: activation of mast cells, epithelial cells, macrophages and dendritic cells
Immune profile induced: Th2-biased

Route of immunization: IM and IN
Point of Contact: Herman Staats, Duke University",,,Th2-biased immune profile,,,,,,,
VO:0005381,Mast cell activator small molecules vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,Mast cell activator small molecules,,https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991,Herman Staats|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: mast cell activation
Immune profile induced: Th2-biased

Route of immunization: IN
Point of Contact: Herman Staats, Duke University",,,Th2-biased immune profile,,,,,,,
VO:0005382,Precision Vaccines Program (PVP)-037 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,Precision Vaccines Program (PVP)-037,,,Ofer Levy|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital",,,Th1-biased immune profile,,,,,,,
VO:0005383,BECC470s vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,BECC470s,,,Robert Ernst|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: TLR4 agonist
Immune profile induced: Th1/Th2

Route of immunization: IM and IN
Point of Contact: Robert Ernst, University of Maryland - Baltimore",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005384,TRAC478 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,TRAC478,,,Helene Bazin-Lee|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",,Toll-like receptor 4 | Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005385,GLA-3M-052-LS vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,GLA-3M-052-LS,,https://www.ncbi.nlm.nih.gov/pubmed/?term=34248966|https://www.ncbi.nlm.nih.gov/pubmed/?term=34795290,Christopher Fox|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1/Th17

Route of immunization: IM and IN
Point of Contact: Christopher Fox, AAHI",,Toll-like receptor 4,Th1/Th17 mixed immune profile,,,,,,,
VO:0005386,3M-052-SE vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,3M-052-SE,,https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728|https://www.ncbi.nlm.nih.gov/pubmed/?term=30089691|https://www.ncbi.nlm.nih.gov/pubmed/?term=32213623|https://www.ncbi.nlm.nih.gov/pubmed/?term=34131024|https://www.ncbi.nlm.nih.gov/pubmed/?term=34972105|https://www.ncbi.nlm.nih.gov/pubmed/?term=35572573,Christopher Fox|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI",,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005387,3M-052-Alum vaccine adjuvant,vaccine adjuvant,VAC,aluminum vaccine adjuvant,3M-052-Alum,,https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326|https://www.ncbi.nlm.nih.gov/pubmed/?term=32561559|https://www.ncbi.nlm.nih.gov/pubmed/?term=33971664|https://www.ncbi.nlm.nih.gov/pubmed/?term=34117252|https://www.ncbi.nlm.nih.gov/pubmed/?term=34266981,Christopher Fox|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT04915768
https://clinicaltrials.gov/ct2/show/NCT05197712",,,Th1-biased immune profile,,,,,,,
VO:0005388,SWE vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,SWE,,https://www.ncbi.nlm.nih.gov/pubmed/?term=30849373|https://www.ncbi.nlm.nih.gov/pubmed/?term=32411401,Patrice Dubois|Wolfgang Leitner|Oliver He,"Chemical Nature: (1) emulsion
Mechanism of Action: unknown
Immune profile induced: Th1/Th17

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute

Clinical trial:
https://clinicaltrials.gov/ct2/show/NCT04702178",,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005389,SQ vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,SQ,,https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647,Patrice Dubois|Wolfgang Leitner|Oliver He,"Chemical Nature: (1) Emulsion (with Saponin)
Mechanism of Action: unknown
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute",,,Th1-biased immune profile,,,,,,,
VO:0005390,LQ vaccine adjuvant,vaccine adjuvant,VAC,saponin vaccine adjuvant,LQ,,https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809|https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647,Patrice Dubois|Wolfgang Leitner|Oliver He,"Chemical Nature: (1) other (liposome with Saponin)
Mechanism of Action: unknown
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute",,,Th1-biased immune profile,,,,,,,
VO:0005419,MicroCrystalline Tyrosine vaccine adjuvant,vaccine adjuvant,VAC,particulate antigen delivery system vaccine adjuvant,MCT|MCT vaccine adjuvant|MicroCrystalline Tyrosine|MicroCyrstalline Tyrosine® (MCT),,https://www.ncbi.nlm.nih.gov/pubmed/?term=28347293|https://www.ncbi.nlm.nih.gov/pubmed/?term=28468322|https://www.ncbi.nlm.nih.gov/pubmed/?term=28953265|https://www.ncbi.nlm.nih.gov/pubmed/?term=29592962,Matthew Heath|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: Activation of APCs, activation of T cells and stimulating B cell proliferation (IgG)
Immune profile induced: Th1-biased

Route of immunization: IM and SQ
Point of Contact: Matthew Heath, Allergy Therapeutics (UK) Ltd",,,Th1-biased immune profile,,,,,,,
VO:0005420,GLA-SE vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,GLA-SE,,https://clinicaltrials.gov/ct2/show/NCT01484548|https://clinicaltrials.gov/ct2/show/NCT01751048|https://clinicaltrials.gov/ct2/show/NCT02071758|https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089|https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869|https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329
https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=21816196
https://www.ncbi.nlm.nih.gov/pubmed/?term=21690242
https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869
https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184
https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184
https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649
https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649
https://www.ncbi.nlm.nih.gov/pubmed/?term=22509423
https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687
https://www.ncbi.nlm.nih.gov/pubmed/?term=23904160
https://www.ncbi.nlm.nih.gov/pubmed/?term=23954378
https://www.ncbi.nlm.nih.gov/pubmed/?term=22425788
https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286
https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286
https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057
https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057
https://www.ncbi.nlm.nih.gov/pubmed/?term=23228811
https://www.ncbi.nlm.nih.gov/pubmed/?term=25024362
https://www.ncbi.nlm.nih.gov/pubmed/?term=25030053
https://www.ncbi.nlm.nih.gov/pubmed/?term=24404140
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898
https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898
https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521
https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521
https://www.ncbi.nlm.nih.gov/pubmed/?term=25367751
https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135
https://www.ncbi.nlm.nih.gov/pubmed/?term=25637347
https://www.ncbi.nlm.nih.gov/pubmed/?term=27005808
https://www.ncbi.nlm.nih.gov/pubmed/?term=26656121
https://www.ncbi.nlm.nih.gov/pubmed/?term=26874325
https://www.ncbi.nlm.nih.gov/pubmed/?term=26791076
https://www.ncbi.nlm.nih.gov/pubmed/?term=27466350
https://www.ncbi.nlm.nih.gov/pubmed/?term=27699241
https://www.ncbi.nlm.nih.gov/pubmed/?term=29176865
https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370
https://www.ncbi.nlm.nih.gov/pubmed/?term=29263879
https://www.ncbi.nlm.nih.gov/pubmed/?term=29795025
https://www.ncbi.nlm.nih.gov/pubmed/?term=29983563
https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252
https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252
https://www.ncbi.nlm.nih.gov/pubmed/?term=27895131
https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844
https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075
https://www.ncbi.nlm.nih.gov/pubmed/?term=33705411
https://www.ncbi.nlm.nih.gov/pubmed/?term=35126135
https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214
https://www.ncbi.nlm.nih.gov/pubmed/?term=26731269
https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448
https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448
https://www.ncbi.nlm.nih.gov/pubmed/?term=27456709
https://www.ncbi.nlm.nih.gov/pubmed/?term=32023469
https://www.ncbi.nlm.nih.gov/pubmed/?term=32402293
https://www.ncbi.nlm.nih.gov/pubmed/?term=32348377
https://www.ncbi.nlm.nih.gov/pubmed/?term=32697993
https://www.ncbi.nlm.nih.gov/pubmed/?term=29515589
https://www.ncbi.nlm.nih.gov/pubmed/?term=33046728
https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678
https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937
https://www.ncbi.nlm.nih.gov/pubmed/?term=30567978
https://www.ncbi.nlm.nih.gov/pubmed/?term=31362695
https://www.ncbi.nlm.nih.gov/pubmed/?term=29769270
https://www.ncbi.nlm.nih.gov/pubmed/?term=31521953
https://www.ncbi.nlm.nih.gov/pubmed/?term=28298421

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT01484548
https://clinicaltrials.gov/ct2/show/NCT01751048
https://clinicaltrials.gov/ct2/show/NCT02071758
https://clinicaltrials.gov/ct2/show/NCT02465216
https://clinicaltrials.gov/ct2/show/NCT01927159
https://clinicaltrials.gov/ct2/show/NCT01599897
https://clinicaltrials.gov/ct2/show/NCT01154049
https://clinicaltrials.gov/ct2/show/NCT03302897
https://clinicaltrials.gov/ct2/show/NCT02465216
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT03806686
https://clinicaltrials.gov/ct2/show/NCT01949909
https://clinicaltrials.gov/ct2/show/NCT01540474
https://clinicaltrials.gov/ct2/show/NCT02014727
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT02658253
https://clinicaltrials.gov/ct2/show/NCT01991561
https://clinicaltrials.gov/ct2/show/NCT01596725
https://clinicaltrials.gov/ct2/show/NCT01147068
https://clinicaltrials.gov/ct2/show/NCT03820414
https://clinicaltrials.gov/ct2/show/NCT03220724
https://clinicaltrials.gov/ct2/show/NCT03409276
https://clinicaltrials.gov/ct2/show/NCT01864876
https://clinicaltrials.gov/ct2/show/NCT02115815
https://clinicaltrials.gov/ct2/show/NCT01397604",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005421,GLA-SLQ vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,GLA-SLQ,,https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687|https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505|https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135|https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758|https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937|https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Mixed Th1/Th2

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT03589794",,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005422,SLA-LSQ vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,SLA-LSQ,,https://www.ncbi.nlm.nih.gov/pubmed/?term=30302281,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005423,SLA-SE vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,SLA-SE,,https://www.ncbi.nlm.nih.gov/pubmed/?term=30386348|https://www.ncbi.nlm.nih.gov/pubmed/?term=31149350|https://www.ncbi.nlm.nih.gov/pubmed/?term=31891152|https://www.ncbi.nlm.nih.gov/pubmed/?term=32540272|https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: n/a

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT03820414
https://clinicaltrials.gov/ct2/show/NCT02071758",,Toll-like receptor 4,,,,,,,,
VO:0005424,GLA-AF vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,GLA-AF,,https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687|https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505|https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135|https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758|https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937|https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT03589794",,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005471,MAS-1 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,MAS-1,A vaccine adjuvant 30:70 (w/w) Water-in-Oil  (W/O) emulsion that stimulates a mixed Th1/Th2 response.,https://clinicaltrials.gov/ct2/show/NCT02118077|https://clinicaltrials.gov/ct2/show/NCT02500680|https://clinicaltrials.gov/ct2/show/NCT03624062|https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760|https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964|https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319|https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305,Peter Blackburn|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: emulsion
Mechanism of Action: adjuvanted antigen depot at injection site
Immune profile induced: Mixed Th1/Th2

Route of immunization: IM and SQ
Point of Contact: Peter Blackburn, MerciaPharma

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760
https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964
https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319
https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT02500680
https://clinicaltrials.gov/ct2/show/NCT02500680
https://clinicaltrials.gov/ct2/show/NCT03624062
https://clinicaltrials.gov/ct2/show/NCT02118077",,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005472,ProLNG-S vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,ProLNG-S,A vaccine adjuvant that induces CD8 T cells and provides innate protection.,https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335,Taegyan Kang|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: SQ
Point of Contact: Taegyan Kang, Progeneer

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335

Ongoing clinical trials: n/a",,,Th1-biased immune profile,,,,,,,
VO:0005473,CAF09b vaccine adjuvant,vaccine adjuvant,VAC,liposome-based vaccine adjuvant,CAF09b,A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response.,https://clinicaltrials.gov/ct2/show/NCT03715985|https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684|https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074|https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772,Gabriel Kristian Pedersen|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Liposome
Mechanism of Action: n/a
Immune profile induced: n/a

Route of immunization: IN, IP, IM,
Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI)

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772
https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684
https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03715985",,,Th1-biased immune profile,,,,,,,
VO:0005474,3M-052-AF vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,3M-052-AF,A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed.,https://clinicaltrials.gov/ct2/show/NCT04177355|https://clinicaltrials.gov/ct2/show/NCT04915768|https://clinicaltrials.gov/ct2/show/NCT05471076|https://clinicaltrials.gov/ct2/show/NCT05781542|https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326|https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326
https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326
https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT05781542
https://clinicaltrials.gov/ct2/show/NCT05471076
https://clinicaltrials.gov/ct2/show/NCT04915768
https://clinicaltrials.gov/ct2/show/NCT05781542",,Toll-like receptor,Th1-biased immune profile,,,,,,,
VO:0005475,NanoAlum vaccine adjuvant,vaccine adjuvant,VAC,aluminum vaccine adjuvant,NanoAlum,"A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response.",https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742|https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742
https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264",,,Th1-biased immune profile,,,,,,,
VO:0005476,Nanostructured Lipid Carrier (NLC) vaccine adjuvant,vaccine adjuvant,VAC,liposome-based vaccine adjuvant,NLC vaccine adjuvant|Nanostructured Lipid Carrier|Nanostructured Lipid Carrier (NLC),A vaccine adjuvant is a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens.,https://clinicaltrials.gov/ct2/show/NCT05370040|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388|https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783|https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728|https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666|https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728
https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202
https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388
https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783
https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712
https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT05370040",,,Th1-biased immune profile,,,,,,,
VO:0005482,SLA-AF vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,SLA-AF,A vaccine adjuvant is an oil-in-water emulsion that induces Th1-based immune response.,https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577|https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: n/a

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577
https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225",,Toll-like receptor,Th1-biased immune profile,,,,,,,
VO:0005483,CAF01 vaccine adjuvant,vaccine adjuvant,VAC,liposome-based vaccine adjuvant,CAF01|CAF-01,A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response.,https://clinicaltrials.gov/ct2/show/NCT00922363|https://clinicaltrials.gov/ct2/show/NCT01009762|https://clinicaltrials.gov/ct2/show/NCT01141205|https://clinicaltrials.gov/ct2/show/NCT02787109|https://clinicaltrials.gov/ct2/show/NCT03926728|https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936|https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731|https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776|https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939|https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790|https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987|https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488|https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263|https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110,Gabriel Kristian Pedersen|Ari Joffe|Wolfgang Leitner|Oliver He,"Chemical Nature: Liposome system
Mechanism of Action: n/a
Immune profile induced: Th1/Th17

Route of immunization: IP, IM, IN, SQ, ID, SC, SL, intratracheal, endotracheal, Fish vaccination
Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI)

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263
https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488
https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790
https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110
https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776
https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936
https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987
https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731
https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939
https://www.ncbi.nlm.nih.gov/pubmed/?term=33072125
https://www.ncbi.nlm.nih.gov/pubmed/?term=35585969
https://www.ncbi.nlm.nih.gov/pubmed/?term=26494626
https://www.ncbi.nlm.nih.gov/pubmed/?term=26379666
https://www.ncbi.nlm.nih.gov/pubmed/?term=35124896
https://www.ncbi.nlm.nih.gov/pubmed/?term=34358167
https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075
https://www.ncbi.nlm.nih.gov/pubmed/?term=31130946
https://www.ncbi.nlm.nih.gov/pubmed/?term=31906072
https://www.ncbi.nlm.nih.gov/pubmed/?term=32106599
https://www.ncbi.nlm.nih.gov/pubmed/?term=19492047
https://www.ncbi.nlm.nih.gov/pubmed/?term=33422991
https://www.ncbi.nlm.nih.gov/pubmed/?term=28414746
https://www.ncbi.nlm.nih.gov/pubmed/?term=33066267
https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370
https://www.ncbi.nlm.nih.gov/pubmed/?term=23308247
https://www.ncbi.nlm.nih.gov/pubmed/?term=30984200
https://www.ncbi.nlm.nih.gov/pubmed/?term=20505822
https://www.ncbi.nlm.nih.gov/pubmed/?term=27525651
https://www.ncbi.nlm.nih.gov/pubmed/?term=23873630

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT00922363
https://clinicaltrials.gov/ct2/show/NCT01009762
https://clinicaltrials.gov/ct2/show/NCT02787109
https://clinicaltrials.gov/ct2/show/NCT01141205
https://clinicaltrials.gov/ct2/show/NCT03926728",,C-type lectin domain family 4 member E,Th1/Th17 mixed immune profile,,,,,,,
VO:0005507,Bl-Eng2 vaccine adjuvant,vaccine adjuvant,VAC,microbial derivative vaccine adjuvant,Bl-Eng2,Vaccine adjuvant that is primarily composed of protein and actives innate immune pathways to induce a mixed Th1/Th2 response.,Pubmed:28793349|Pubmed:31900406,Nilufer kosar|Jie Zheng|Marcel Wuethrich,"Chemical Nature: protein
Mechanism of Action: Activation of innate immune pathways
Immune profile induced: Th1/Th2

Route of immunization: SC, IN, SQ
Point of Contact: Marcel Wuethrich, University of Wisconsin

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=28793349
https://www.ncbi.nlm.nih.gov/pubmed/?term=31900406

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/730,C-type lectin domain family 6 member A | C-type lectin domain family 4 member E,Th1/Th2 mixed immune profile,,,,,,,
VO:0005508,Bl-Eng2+Adjuplex vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,Bl-Eng2+Adjuplex,Combination vaccine adjuvant contains both Bl-Eng2 and adjuplex vaccine adjuvants and is able to induce a mixed Th1/Th2 response.,Pubmed:33735218,Nilufer kosar|Jie Zheng|Marcel Wuethrich,"Chemical Nature: Protein, Combination adjuvant
Mechanism of Action: Activation of innate immune pathways
Immune profile induced: Th1/Th2

Route of immunization: IN
Point of Contact: Marcel Wuethrich, University of Wisconsin

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=33735218

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/731,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005509,IL-12-MOP (CTX-1796) vaccine adjuvant,vaccine adjuvant,VAC,nucleic acid vaccine adjuvant,IL-12-MOP (CTX-1796),Nucleic acid vaccine adjuvant that targets on cytokine receptor to induce a Th1-based response.,Pubmed:39047117,Nilufer kosar|Jie Zheng|Romain Micol,"Chemical Nature: nucleic acid
Mechanism of Action: Cytokine Receptor
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Romain Micol, Combined Therapeutics

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=39047117

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/740,,Th1-biased immune profile,,,,,,,
VO:0005510,EVAX-B vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,EVAX-B,"Botryococcene oil-in-water emulsion vaccine adjuvant made by EVAX Inc., which targets to induce a mixed Th1/Th2 response.",Pubmed:33051497,Nilufer kosar|Jie Zheng|Chase Kempinski,"Chemical Nature: Emulsion
Mechanism of Action: Botryococcene oil-in-water emulsion
Immune profile induced: Mixed Th1/Th2
Route of immunization: SQ
Point of Contact: Chase Kempinski , EVAX Inc.
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=33051497
Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/759,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005511,EVAX-S vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,EVAX-S,"Squalene oil-in-water emulsion vaccine adjuvant made by EVAX Inc., which targets to induce a mixed Th1/Th2 response.",Pubmed:33051497,Nilufer kosar|Jie Zheng|Chase Kempinski,"Chemical Nature: Emulsion
Mechanism of Action: Squalene oil-in-water emulsion
Immune profile induced: Mixed Th1/Th2

Route of immunization: SQ
Point of Contact: Chase Kempinski , EVAX Inc.

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=33051497

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/760,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005512,ME-F-1051 (VesiVax®) vaccine adjuvant,vaccine adjuvant,VAC,liposome-based vaccine adjuvant,ME-F-1051 (VesiVax®)|ME-F-1051,Vaccine adjuvant based on VesiVax® liposome.,Pubmed:16713037|Pubmed:19835825|Pubmed:21545821|Pubmed:23313243|Pubmed:26312747|Pubmed:27997339|Pubmed:28922045|Pubmed:29420901|Pubmed:3568049,Jie Zheng|Gary Fujii|Molecular Express,"Chemical Nature: VesiVax® liposome
Mechanism of Action: none
Immune profile induced: none

Route of immunization: SQ prime and IN boost, SQ, Combination sub-cheek, IN and ID, IN prime and sub-cheek boosts
Point of Contact: Gary Fujii, Molecular Express

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037
https://www.ncbi.nlm.nih.gov/pubmed/?term=17981684
https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825
https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821
https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243
https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747
https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339
https://www.ncbi.nlm.nih.gov/pubmed/?term=28922045
https://www.ncbi.nlm.nih.gov/pubmed/?term=29420901
https://www.ncbi.nlm.nih.gov/pubmed/?term=3568049

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/784,,,,,,,,,
VO:0005513,ME-F-1122 vaccine adjuvant,vaccine adjuvant,VAC,liposome-based vaccine adjuvant,ME-F-1122,ME-F-1122 is a Liposome-based vaccine adjuvant with TLR4 agonist to induce a mixed Th1/Th2 response..,Pubmed:23313243|Pubmed:26312747|Pubmed:27997339|Pubmed:35680499|Pubmed:19835825|Pubmed:21545821|Pubmed:16713037,Jie Zheng|Gary Fujii|Molecular Express,"Chemical Nature: Natural compound - Liposome formulation with TLR4 agonist
Mechanism of Action: none
Immune profile induced: Mixed Th1/Th2

Route of immunization: SQ, Combination of sub-cheek, IN and ID, IN prime with sub-cheek boosts,
Point of Contact: Gary Fujii, Molecular Express

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243
https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747
https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339
https://www.ncbi.nlm.nih.gov/pubmed/?term=35680499
https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825
https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821
https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/785,,Th1-biased immune profile,,,,,,,
VO:0005514,CpG 1018 vaccine adjuvant,vaccine adjuvant,VAC,CpG DNA vaccine adjuvant,CpG 1018|ISS 1018 CpG ODN|ISS 1018 CpG oligodeoxynucleotide|ISS-1018,Short class B CpG-containing sequence with phosphorothioate-linked nucleotides that is able to induce a Th1-biased response.,Pubmed:24464743|Pubmed:33649322|Pubmed:33873199|Pubmed:33888840|Pubmed:38570604|Pubmed:35927132|Pubmed:35869085|Pubmed:37703367|Pubmed:39231203|https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iss-1018-cpg-oligodeoxynucleotide|https://www.drugbank.ca/drugs/DB05463,Jie Zheng|Ben Wizel|Dynavax,"Chemical Nature: Nucleic acid
Mechanism of Action: CpG 1018 is a short class B CpG-containing sequence with phosphorothioate-linked nucleotides
Immune profile induced: Th1-biased

Route of immunization: IN, IM
Point of Contact: Ben Wizel, Dynavax

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=24464743
https://www.ncbi.nlm.nih.gov/pubmed/?term=33649322
https://www.ncbi.nlm.nih.gov/pubmed/?term=33873199
https://www.ncbi.nlm.nih.gov/pubmed/?term=33888840
https://www.ncbi.nlm.nih.gov/pubmed/?term=38570604
https://www.ncbi.nlm.nih.gov/pubmed/?term=35927132
https://www.ncbi.nlm.nih.gov/pubmed/?term=35869085
https://www.ncbi.nlm.nih.gov/pubmed/?term=37703367
https://www.ncbi.nlm.nih.gov/pubmed/?term=39231203

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/ACTRN12624000064505
https://clinicaltrials.gov/ct2/show/NCT06334393
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT04672395
https://clinicaltrials.gov/ct2/show/NCT05188677
https://clinicaltrials.gov/ct2/show/NCT05011526
https://clinicaltrials.gov/ct2/show/NCT05364242
https://clinicaltrials.gov/ct2/show/NCT04956224
https://clinicaltrials.gov/ct2/show/NCT0486456
https://clinicaltrials.gov/ct2/show/ACTRN12620001177943
https://clinicaltrials.gov/ct2/show/NCT00251394
https://clinicaltrials.gov/ct2/show/NCT01282762
https://clinicaltrials.gov/ct2/show/NCT00346086
https://clinicaltrials.gov/ct2/show/NCT06569823
https://clinicaltrials.gov/ct2/show/NCT05245838
https://clinicaltrials.gov/ct2/show/NCT05506969",https://github.com/vaccineontology/VO/issues/787,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005515,7DW8-5 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,7DW8-5,"Small molecule, synthetic derivative of natural compound (galactosylceramide) that induces Th1/Th2/Th17 response.",PMID:28483194,Jie Zheng|Moriya Tsuji|Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005516,1P7 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,1P7,1P7 is a CpG DNA vaccine adjuvant.,PMID:18479788,Josh Monickaraj,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005517,3DSNA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,3DSNA,3DSNA is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:31244959,Taiyu Lin,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005518,3pRNA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,3pRNA,Triphosphate RNA (3pRNA) is a RIG-I Ligand.,PMID:26819202,Yuping Zheng,,,interferon-induced helicase C domain-containing protein 1,Th1-biased immune profile,,,,,,,
VO:0005519,TLR1 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR1 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 1,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 1'),,,,,
VO:0005520,ADP-ribosylating vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,ADP-ribosylating adjuvant,ADP-ribosylating adjuvant is a microbial derivative vaccine adjuvant that induces Th1/Th17 mixed immune profile.,PMID:35418673,Le Liu,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005521,AH:CpG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,AH:CpG,AH:CpG is a combination vaccine adjuvant that induces Th1-biased immune profile.,PMID:34031655,Le Liu,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005522,Aikejia vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Aikejia,Aikejia is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:31293651,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005523,Al-BSA-Ce6 NPs vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,Al-BSA-Ce6 NPs,Al-BSA-Ce6 NPs is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:32240675,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005524,Alarmin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,Alarmin|Alarmin IL-33,"A substance that signals tissue and cell damage. In this context, it refers to Interleukin-33 (IL-33).",PMID:24448242,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005525,ALF vaccine adjuvant,vaccine adjuvant,AdjuvareDB,liposome-based vaccine adjuvant,ALF,"A family of anionic liposome-based adjuvants containing synthetic phospholipids, cholesterol, and monophosphoryl lipid A (MPLA).",PMID:29432824,Yuping Zheng,,,,Th2-biased immune profile,,,,,,,
VO:0005526,Algel-IMDQ vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,Algel-IMDQ,Algel-IMDQ is a combination vaccine adjuvant that induces Th1-biased immune profile.,PMID:33485468,Le Liu,,,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005527,AlO(OH)-polymer nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,AlO(OH)-polymer nanoparticles,AlO(OH)-polymer nanoparticles is a Nano-sized vaccine carriers derived from aluminum hydroxide gel..,PMID:29375970,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005528,Alum and IL-10 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,Alum and IL-10,"Alum refers to Aluminium adjuvant or Alum Compounds, which are Adjuvants, Immunologic used in vaccines to enhance the immune response. IL-10 is a key cytokine that limits excessive immune responses.",PMID:29349774,Yuping Zheng,,,,Th2-biased immune profile,,,,,,,
VO:0005529,Alum/CpG-based formulation vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,Alum/CpG-based formulation,A combination of aluminum-containing adjuvants (Alum) with oligodeoxynucleotides containing CpG motifs (a TLR9 agonist) adsorbed to Alum.,PMID:28220116,Yuping Zheng,,,Toll-like receptor 9,Th1/Th2 mixed immune profile,,,,,,,
VO:0005530,AmpB vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,AmpB,AmpB is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:30470547,Taiyu Lin,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005531,ANXA2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,ANXA2,"Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein found intracellularly, membrane-bound, or secreted, existing as a monomer or heterotetramer. Monomeric ANXA2 (ANXA2m), particularly when overexpressed in low-oxygen conditions, acts as an adjuvant by inducing dendritic cell maturation through TLR2.",PMID:26885373,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005532,AP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,AP adjuvant,AP adjuvant is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:34766215,Le Liu,,,Toll-like receptor 3,Th1-biased immune profile,,,,,,,
VO:0005533,APS vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,APS,Ccarbohydrate vaccine adjuvant that induces a mixed Th1/Th2 response,PMID:23006659,Josh Monickaraj,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005534,AS01 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,AS01,"An Adjuvant System consisting of a TLR4 ligand, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21.",PMID:29263880,Yuping Zheng,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005535,Babassu aqueous extract vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Babassu aqueous extract,Carbohydrate vaccine adjuvant that induces a Th1 response,PMID:21276258,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005536,BVP22 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,fusion protein vaccine adjuvant,BVP22,BVP22 is a fusion protein adjuvant that induces TH1 reponse.,PMID:11440628|PMID:22720700,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005537,C3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,fusion protein vaccine adjuvant,C3 adjuvant,C3 adjuvant is a molecular adjuvant that induces Th2 response.,PMID:16944576|PMID:8553069|PMID:11429124,Josh Monickaraj,,,,Th2-biased immune profile,,,,,,,
VO:0005538,C60(OH)22 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,C60(OH)22,C60(OH)22 is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:30678964,Taiyu Lin,,,Toll-like receptor,Th1-biased immune profile,,,,,,,
VO:0005539,CA-CpG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CA-CpG,Carbonate apatite (CA) nanoparticles containing CpG oligodeoxynucleotides (ODNs).,PMID:29720976,Yuping Zheng,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005540,CAF04 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CAF04,Combination vaccine adjuvant contains CAF04 Th1-biased immune profile.,PMID:29964134,Taiyu Lin,,,C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0005541,CAF05 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CAF05,CAF05 is a combination vaccine adjuvant that induces a mixed Th1/Th17 response.,PMID:22095092,Josh Monickaraj,,,Toll-like receptor 3,Th1/Th17 mixed immune profile,,,,,,,
VO:0005542,CAF06 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CAF06,CAF06 is a synthetic vaccine adjuvant that induces mixed Th1/Th17 response.,PMID:21042837|PMID:30396811,Josh Monickaraj,,,C-type lectin domain family 4 member E,Th1/Th17 mixed immune profile,,,,,,,
VO:0005543,CAF19 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,CAF19,A nanoemulsion-based adjuvant containing a synthetic CMI-inducing mycobacterial monomycoloyl glycerol (MMG) analogue.,PMID:28516400,Yuping Zheng,,,C-type lectin domain family 4 member E,Th1/Th2 mixed immune profile,,,,,,,
VO:0005544,CAF23 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CAF23,Combination vaccine adjuvant contains CAF23 Th1-biased immune profile.,PMID:30609354,Taiyu Lin,,,C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0005545,CAF24a vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CAF24a,"A nanoemulsion engineered from the active components of CAF09 (dimethyldioctadecylammonium bromide, a synthetic monomycoloyl glycerol analog, and polyinosinic:polycytidylic acid), with a biodegradable squalane oil phase and varied surface charge by replacing DDA with zwitterionic distearoylphosphoethanolamine.",PMID:29760705,Yuping Zheng,,,Toll-like receptor 3 | C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0005546,Candida skin test reagent vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Candida skin test reagent,microbial derivative vaccine adjuvant from C. albicans that induces a mixed Th1/Th17 response,PMID:24135577|PMID:30245818,Josh Monickaraj,,,C-type lectin domain family 7 member A,Th1/Th17 mixed immune profile,,,,,,,
VO:0005547,carbon-silica nanocomposite vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,carbon-silica nanocomposite,carbon-silica nanocomposite is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:31909977,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005548,caspase-1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,caspase-1,caspase-1 is a cytokine vaccine adjuvant that induces Th1/Th17 mixed immune profile.,PMID:35177300,Le Liu,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005549,CBP-12 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CBP-12,CBP-12 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:34158852,Le Liu,,,C-type lectin domain family 9 member A,Th1-biased immune profile,,,,,,,
VO:0005550,CCL19 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CCL19,CCL19 is a cytokine vaccine adjuvant that prodices a mixed Th1/Th2 response.,PMID:23099886,Josh Monickaraj,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005551,CCL21 and IL1β vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CCL21 and IL1β,CCL21 and IL1β is a combination vaccine adjuvant that induces Th1/Th17 mixed immune profile.,PMID:36037155,Le Liu,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005552,GPI-CCL28 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,GPI-CCL28,"A Chemokine, CC and Ccl28 protein, mouse, functioning as a mucosal adjuvant when GPI-anchored.",PMID:28067290,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005553,CCL3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CCL3 adjuvant|CCL3,CCL3 adjuvant is a cytokine vaccine adjuvant that induces Th1 response.,PMID:20420712,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005554,CCL34 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CCL34,CCL34 is a cytokine vaccine adjuvant Th1-biased immune profile.,PMID:32439945,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005555,CCL5 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CCL5 adjuvant,CCL5 adjuvant is a cytokine vaccine adjuvant that induces Th1 response.,PMID:20233026,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005556,CD226 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CD226,"A co-stimulatory molecule belonging to the immunoglobulin superfamily, which is expressed on most NK cells, T cells, monocytes, and platelets, contributing to both innate and adaptive immune responses.",PMID:25582686,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005557,CDG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,CDG,A vaccine adjuvant that is the bacterial second messenger (3'-5')-cyclic-di-guanosine-monophosphate (c-di-GMP).,PMID:24307739,Yuping Zheng,,,protein MB21D1,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0005558,CGAMP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,CGAMP,CGAMP is a nucleic acid vaccine adjuvant that produces a mixed Th1/Th2 response.,PMID:23989956|PMID:36420215,Josh Monickaraj,,,protein MB21D1,Th1/Th2 mixed immune profile,,,,,,,
VO:0005559,Chitin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,Chitin,"Carbohydrate vaccine adjuvant that induces bisaed Th2 response, but also smaller Th1/Th17 responses",PMID:20656945,Josh Monickaraj,,,C-type lectin domain family 7 member A | Toll-like receptor 2 | protein MB21D1,Th2-biased immune profile,,,,,,,
VO:0005560,CITCO vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CITCO,CITCO is a cytokine vaccine adjuvant that induces Th1-biased immune profile.,PMID:33233444,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005573,CL429 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CL429,CL429 is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:30470547,Taiyu Lin,,,Toll-like receptor 2 | Toll-like receptor 6 | Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005574,CnB vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CnB,CnB is a synthetic vaccine adjuvant that induces Th1 response.,PMID:21447603|PMID:22652401,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005575,CoVaccine HT™ vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,CoVaccine HT™,CoVaccine HT™ is a emulsion vaccine adjuvant that induces Th1-biased immune profile.,PMID:33688645,Le Liu,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005576,CPG 7909 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,CPG 7909,CPG 7909 is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.,PMID:37696935,Le Liu,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005577,CpG and DcMNP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CpG and DcMNP,"CpG refers to CpG-oligodeoxynucleotide (CpG-ODN), which functions as an immune adjuvant. DcMNPs are PAMAM dendrimer-coated magnetic nanoparticles.",PMID:27717915,Yuping Zheng,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005578,CpG M362 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,CpG M362,CpG M362 is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.,PMID:34975324,Le Liu,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005579,CpG oligodeoxynucleotide 1826 (CAF10) vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,CpG oligodeoxynucleotide 1826 (CAF10)|CpG oligodeoxynucleotide 1826,A Toll-like receptor 9 (TLR9) ligand.,PMID:25529567,Yuping Zheng,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005580,CpG-MUC1-hydrogel vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CpG-MUC1-hydrogel,CpG-MUC1-hydrogel is a combination vaccine adjuvant Th1-biased immune profile.,PMID:31747745,Taiyu Lin,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005581,CpG-ODN and Coa-ASC16 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,CpG-ODN and Coa-ASC16,CpG-ODN and Coa-ASC16 is a combination vaccine adjuvant Th1-biased immune profile.,PMID:30364187,Taiyu Lin,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005582,Cry protein vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Cry protein,"Insecticidal crystal proteins from Bacillus thuringiensis (Bt) bacteria, primarily used in GM crops for insect resistance.",PMID:27105772,Yuping Zheng,,,Toll-like receptor 4,,,,,,,,
VO:0005583,CS3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,CS3 adjuvant,Carbohydrate vaccine adjuvant that induces a mixed Th1/Th17 response,PMID:16514157,Josh Monickaraj,,,Toll-like receptor 2 | Toll-like receptor 4 | C-type lectin domain family 7 member A,Th1/Th17 mixed immune profile,,,,,,,
VO:0005584,CTA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,CTA,Cholera Toxin A (CTA) is a protein that can be used as a genetic adjuvant for DNA vaccines. It enhances the immune response by its ADP-ribosyltransferase activity.,PMID:24631089,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005585,CTA1-M2e-DD vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cholera toxin derived vaccine adjuvant,CTA1-M2e-DD,Cholera toxin derived vaccine adjuvant that induces a Th17 response,PMID:18243429,Josh Monickaraj,,,,Th17-biased immune profile,,,,,,,
VO:0005586,CTA2B vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,cholera toxin derived vaccine adjuvant,CTA2B,Cholera toxin derived vaccine adjuvant that induces Th1 response,,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005587,CTB vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,CTB,Cholera toxin subunit B (CTB) is a protein that can be used as a genetic adjuvant to enhance immune responses.,PMID:24741585,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005588,curcumin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,curcumin,curcumin is a plant-derived vaccine adjuvant that induces Th1-biased immune profile.,PMID:34485117,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005589,CVC1302 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,CVC1302,CVC1302 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:34867941,Le Liu,,,Toll-like receptor 4 | nucleotide-binding oligomerization domain-containing protein 2 | C-type lectin domain family 7 member A,Th1-biased immune profile,,,,,,,
VO:0005590,CXCL10-mucin-GPI vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CXCL10-mucin-GPI,cytokine vaccine adjuvant derived from CXCL10 chemokine head ,PMID:24023642,Josh Monickaraj,,,,,,,,,,,
VO:0005591,CXCL11 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CXCL11,CXCL11 is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:23928465,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005592,CXCL11-Fc vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CXCL11-Fc,CXCL11-Fc is a cytokine vaccine adjuvant.,PMID:23928465,Josh Monickaraj,,,,,,,,,,,
VO:0005593,CXCL9 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CXCL9,CXCL9 is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:23928465,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005594,CyPA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,CyPA,Cyclophilin A (CyPA) is a host protein that can serve as a genetic adjuvant to enhance the immunogenicity of DNA vaccines.,PMID:26305669,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005595,D-mannose vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,D-mannose,A hexose sugar that can be used to improve non-viral gene therapy.,PMID:24884664,Yuping Zheng,,,,Anti-inflammatory immune profile,,,,,,,
VO:0005596,DAI vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,DAI,DAI is a synthetic vaccine adjuvant that induces a Th1 response.,PMID:21157438|PMID:27626058,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005597,DLinDMA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,DLinDMA,DLinDMA is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:33960213,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005598,DOTAP and DP7-C liposomes vaccine adjuvant,vaccine adjuvant,AdjuvareDB,liposome-based vaccine adjuvant,DOTAP and DP7-C liposomes,DOTAP and DP7-C liposomes is a liposome-based vaccine adjuvant that induces Th1-biased immune profile.,PMID:32860927,Le Liu,,,Toll-like receptor 2 | Toll-like receptor 4 | Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005599,epigallocatechin-3-gallate vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,epigallocatechin-3-gallate|EGCG,epigallocatechin-3-gallate is a plant-derived vaccine adjuvant from catechins from green tea that induces mixed Th1/Th2 response.,PMID:23582951|PMID:34868027 ,Josh Monickaraj|Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005600,FimH vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,FimH,FimH is a microbial derivative vaccine adjuvant Th1/Th17 mixed immune profile.,PMID:32132528,Taiyu Lin,,,Toll-like receptor 4,Th1/Th17 mixed immune profile,,,,,,,
VO:0005601,FLAB-PSPA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,FLAB-PSPA,A fusion protein combining flagellin (FlaB) with pneumococcal surface protein A (PspA).,PMID:26223660,Yuping Zheng,,,Toll-like receptor 5,Th1-biased immune profile,,,,,,,
VO:0005602,FLIC vaccine adjuvant,vaccine adjuvant,AdjuvareDB,Flagellin vaccine adjuvant,FLIC,Major structural protein of flagellin in salmonella that induces mixed Th1/Th2 response,PMID:22027714,Josh Monickaraj,,,Toll-like receptor 5,Th1/Th2 mixed immune profile,,,,,,,
VO:0005603,Flt-3 ligand vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,Flt-3 ligand,Flt-3 ligand is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:16563456|PMID:11929774,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005604,Fuc-Sc vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Fuc-Sc,Fuc-Sc is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:34364600,Le Liu,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005605,G2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,G2,A G2 adjuvant that upregulates gene expression and increases the surface expression of the NKG2D receptor on NK cells.,PMID:27183434,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005606,G3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,G3,G3 is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:30348190,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005607,GC@ICG nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,GC@ICG nanoparticle,GC@ICG nanoparticle is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.,PMID:35600886,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005608,Gel-gffy vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,Gel-gffy,Gel-gffy is a particulate antigen delivery system vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:35522938,Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005609,GITRL vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,GITRL,Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand (GITRL) is involved in modulating both innate and adaptive immune responses.,PMID:25772201,Yuping Zheng,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005610,glycated chitosan vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,glycated chitosan,"A novel, non-toxic immunoadjuvant, which is a derivative of chitosan.",PMID:24743733,Yuping Zheng,,,C-type lectin domain family 7 member A | protein MB21D1,Th1-biased immune profile,,,,,,,
VO:0005611,GM3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,GM3,GM3 is a carbohydrate vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:35251040,Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005612,gp63 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,liposome-based vaccine adjuvant,gp63,gp63 is a liposome-based vaccine adjuvant that induces a Th1 response .,PMID:18195029,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005613,Granules of mast cells vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,Granules of mast cells,particulate antigen delivery system vaccine adjuvant from mast cell that induces a mixed Th1/Th2 response,PMID:22266469,Josh Monickaraj,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005614,Granulysin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Granulysin,Granulysin is a microbial derivative vaccine adjuvant that induces Th1 response.,PMID:21051561|PMID:21546794,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005615,Graphene oxide vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Graphene oxide,Graphene oxide is a synthetic vaccine adjuvant that induces a Th1 response.,PMID:23566800|PMID:36371365,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005616,HAV-aCNP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,HAV-aCNP,HAV-aCNP is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:32114177,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005617,HBcAg vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,HBcAg,The core antigen of the Hepatitis B virus.,PMID:27109565,Yuping Zheng,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005618,HBHA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,HBHA,HBHA is a microbial derivative vaccine adjuvant that induces Th1 response.,PMID:21368092,Josh Monickaraj,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005619,hexosomes vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,hexosomes,hexosomes is a emulsion vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:29964134,Taiyu Lin,,,C-type lectin domain family 4 member E,Th1/Th2 mixed immune profile,,,,,,,
VO:0005620,HIV-1 protease vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,HIV-1 protease,HIV-1 protease is a microbial derivative vaccine adjuvant that induces Th1 response.,PMID:20484507,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005621,HMBA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,HMBA,"Hexamethylene bisacetamide (HMBA), a hybrid bipolar compound developed over 30 years ago for its ability to induce terminal differentiation of transformed cells.",PMID:28827286,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005622,HMGB1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,HMGB1,HMGB1 is a microbial derivative vaccine adjuvant that induces Th1 repsonse.,PMID:21544096|PMID:19740322,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005623,IBL027 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,IBL027,An immunobiotic Lactobacillus rhamnosus strain and an immunomodulatory strain Lactobacillus rhamnosus strain IBL027.,PMID:29242218,Yuping Zheng,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005624,IFN-alpha vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IFN-α,IFN-α is a cytokine vaccine adjuvant that induces Th1 repsonse.,PMID:21506646|PMID:16651452|PMID:18249478,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005625,IFN-beta vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IFNβ,IFNβ is a cytokine vaccine adjuvant that induces Th1-biased immune profile.,PMID:34552594,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005626,TLR2 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR2 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 2,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 2'),,,,,
VO:0005627,IL-18 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-18,IL-18 is a cytokine vaccine adjuvant that produces Th1 response.,PMID:24228233|PMID:38140192,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005628,IL-1R1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-1R1,IL-1R1 is a cytokine vaccine adjuvant that induces Th17-biased immune profile.,PMID:35110359,Le Liu,,,,Th17-biased immune profile,,,,,,,
VO:0005629,IL-21 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-21,IL-21 is a cytokine vaccine adjuvant that induces Tfh/Th17 mixed immune profile.,PMID:34491910,Le Liu,,,,Tfh/Th17 mixed immune profile,,,,,,,
VO:0005630,IL-27 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-27,IL-27 is a cytokine vaccine adjuvant that induces Treg-biased immune profile.,PMID:35529885|PMID:33294255,Le Liu,,,,Treg-biased immune profile,,,,,,,
VO:0005631,IL-33 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL33,IL33 is a cytokine vaccine adjuvant Th2-biased immune profile.,PMID:32210964,Taiyu Lin,,,,Th2-biased immune profile,,,,,,,
VO:0005632,IL-36 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-36,IL-36 is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:22968459,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005633,IL-4 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-4,Water soluble cytokine vaccine adjuvant that induces a Th2 response.,https://clinicaltrials.gov/study/NCT00923910,Josh Monickaraj,,,,Th2-biased immune profile,,,,,,,
VO:0005634,IL-7-Fc vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IL-7-Fc,IL-7-Fc is a cytokine vaccine adjuvant that induces Th1 response.,PMID:19950168,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005635,IMP321 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,IMP321|LAG-3|LAG-3Ig|eftilagimod alpha,A LAG-3Ig fusion protein that acts as an adjuvant to induce a more robust and durable cellular antitumor immune response.,PMID:24726012,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005636,IP-PA1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,IP-PA1,"Immunopotentiator from Pantoea agglomerans 1, identified as Pantoea agglomerans LPS.",PMID:26168493,Yuping Zheng,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005637,IPMP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,IPMP,Imiquimod (TLR-7 ligand)-loaded PLGA microparticles.,PMID:26017300,Yuping Zheng,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005638,iron oxide nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,iron oxide nanoparticle|iron oxide nanoparticles,Superparamagnetic Fe3O4 nanoparticles.,PMID:29570298,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005639,IRX-2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,IRX-2,IRX-2 is a multiple cytokine vaccine adjuvant that induces Th1 response.,PMID:20708999,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005640,ISG15 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,ISG15,ISG15 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.,PMID:33115866,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005641,K3-SPG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,K3-SPG,"A second-generation TLR9 agonist, specifically a humanized CpG DNA (K3) complexed with schizophyllan (SPG), and functions as a nonagonistic Dectin-1 ligand.",PMID:29431693,Yuping Zheng,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005642,KML-B vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,KML-B,The B-chain of the Korean mistletoe lectin (KML).,PMID:24859056,Yuping Zheng,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005643,Kynurenine vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Kynurenine,Kynurenine is a synthetic vaccine adjuvant that induces Treg-biased immune profile.,PMID:34305913,Le Liu,,,,Treg-biased immune profile,,,,,,,
VO:0005644,L-NAME vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,L-NAME,L-NAME is a synthetic vaccine adjuvant that induces Th1 response.,PMID:21387108,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005645,L-siRNA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,L-siRNA,L-siRNA is a nucleic acid vaccine adjuvant Th1-biased immune profile.,PMID:31214204,Taiyu Lin,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005646,LIGHT vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,LIGHT,"A member of the TNF superfamily that acts as a costimulatory molecule, promoting the proliferation of human naïve T cells.",PMID:24435162,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005647,Listeriolysin O vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Listeriolysin O,Listeriolysin O is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:31298809,Taiyu Lin,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005648,LP-GMP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,LP-GMP,LP-GMP is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:30127384,Taiyu Lin,,,protein MB21D1,Th1-biased immune profile,,,,,,,
VO:0005649,LT-IIb vaccine adjuvant,vaccine adjuvant,Vaxjo 1.0,E. coli LT toxin derived vaccine adjuvant,LT-IIb,LT-IIb is a E. coli LT toxin derived vaccine adjuvant that induces mixed Th1/Th2 response.,PMID: 25536061,Josh Monickaraj,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005650,Man-TLR7 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Man-TLR7,Man-TLR7 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:34634664,Le Liu,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005651,MCP-3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,MCP-3,MCP-3 is a cytokine vaccine adjuvant that induces Th1 response.,PMID:11529662|PMID:11781181|PMID:17074853,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005652,MDA5 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,MDA5,MDA5 is a synthetic vaccine adjuvant that induces a Th1 response.,PMID:23227156,Josh Monickaraj,,,antiviral innate immune response receptor RIG-I,Th1-biased immune profile,,,,,,,
VO:0005653,MDP-1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,muramyl dipeptide vaccine adjuvant,MDP-1,MDP-1 is a muramyl dipeptide vaccine adjuvant that induces Th1 response.,PMID:20497569,Josh Monickaraj,,,nucleotide-binding oligomerization domain-containing protein 2 | Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005654,mesoporous silica nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,mesoporous silica nanoparticle,A plain mesoporous silica (MS) nanoparticle.,PMID:27226038,Yuping Zheng,,,interferon-inducible protein AIM2,Th1/Th2 mixed immune profile,,,,,,,
VO:0005655,MIP-2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,MIP-2,MIP-2 is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:11134269,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005656,MMG-1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,MMG-1,MMG-1 is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:29964134,Taiyu Lin,,,C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0005657,MSP-102 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,MSP-102,"MSP-102, an engineered FLAGELLIN variant, demonstrated enhanced immunostimulatory effects as an adjuvant. Its efficacy was verified through co-administration with the RBD protein of the COVID-19 virus and the HA protein of the influenza virus, confirming its potential in vaccine formulations. It is a microbial derivative vaccine adjuvant that induces mixed Th1/Th2 response.",https://vac.niaid.nih.gov/view?id=96,Josh Monickaraj,"Chemical Nature: Protein
 Mechanism of Action: Innate Immune Activation
 Immune profile induced: Mixed Th1/Th2
 

 Route of immunization: IN
 Point of Contact: Kyung A Cho, Medispan, Inc.
 

 Ongoing clinical trials:
 none",,Toll-like receptor 5,Th1/Th2 mixed immune profile,,,,,,,
VO:0005658,MUC1 based adjuvant-protein-antigen vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,MUC1 based adjuvant-protein-antigen,MUC1 based adjuvant-protein-antigen is a particulate antigen delivery system vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:32146328,Taiyu Lin,,,Toll-like receptor 7,Th1/Th2 mixed immune profile,,,,,,,
VO:0005659,MyD88 and CD40 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,MyD88 and CD40,A chimeric adjuvant that combines innate and adaptive immune signaling.,PMID:27741278,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005660,Myd88 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Myd88,A widespread Toll-like receptor adaptor molecule that is significant in B cell responses to both infections and vaccinations.,PMID:25003094,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005661,Naltrexone vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Naltrexone,An emerging and effective adjuvant that induces protective cellular and Th1 immune responses against Fasciola hepatica infection.,PMID:29729492,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005662,NP DNA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,NP DNA adjuvant,NP DNA adjuvant is a nucleic acid vaccine adjuvant that induces Th1 response.,PMID:20157605,Josh Monickaraj,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005663,NP-3pRNA-CpG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,NP-3pRNA-CpG,NP-3pRNA-CpG is a combination vaccine adjuvant Th1-biased immune profile.,PMID:32585230,Taiyu Lin,,,Toll-like receptor 9 | interferon-induced helicase C domain-containing protein 1,Th1-biased immune profile,,,,,,,
VO:0005664,NP-R@M-M vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,NP-R@M-M,NP-R@M-M is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:29771487,Taiyu Lin,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005665,OK-432 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,OK-432,OK-432 is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:30402504,Taiyu Lin,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005666,OMPC-TLR2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,OMPC-TLR2,OMPC – TLR2 is a combination vaccine adjuvant Th1-biased immune profile.,PMID:30470547,Taiyu Lin,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005667,Ophiopogonin D vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,Ophiopogonin D,Ophiopogonin D is a plant-derived vaccine adjuvant Th1-biased immune profile.,PMID:30031164,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005668,OVA-csNLCs vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,OVA-csNLCs,OVA-csNLCs is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.,PMID:34411614,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005669,OVA-LNPs vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,OVA-LNPs,OVA-LNPs is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:32645499,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005670,P2Et vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,P2Et,A gallotannin-rich fraction from Caesalpinia spinosa.,PMID:26220604,Yuping Zheng,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005671,PAA:nanoalum vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,PAA:nanoalum,PAA:nanoalum is a combination vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:30622742,Taiyu Lin,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005672,PAMK vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PAMK,PAMK is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:30144550,Taiyu Lin,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005673,PAPE vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PAPE,PAPE is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:32864794,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005674,PEI-PPAS vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PEI-PPAS,PEI-PPAS is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:35367581,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005675,PET Lipid A vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,PET Lipid A,PET Lipid A is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.,PMID:26886334,Le Liu,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005676,PhotothermalPhage vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,PhotothermalPhage,PhotothermalPhage is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.,PMID:34551259,Le Liu,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005677,PI-RI vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,PI-RI, microbial derivative vaccine adjuvant that induces Th1 response,,Josh Monickaraj,,,Toll-like receptor 4 | nucleotide-binding oligomerization domain-containing protein 1,Th1-biased immune profile,,,,,,,
VO:0005678,PI-sRI vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PI-sRI,PI-sRI is a synthetic vaccine adjuvant that induces Th1 response.,,Josh Monickaraj,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005679,Pinaceae-derived nanoemulsions vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,Pinaceae-derived nanoemulsions,Pinaceae-derived nanoemulsions is a emulsion vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:31465981,Taiyu Lin,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005680,PLA-b-P(NAS-co-NVP) vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PLA-b-P(NAS-co-NVP),PLA-b-P(NAS-co-NVP is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:35057003,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005681,plant-derived vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant derived from plant that is added to a vaccine formulation to enhance or modulate the body’s immune response to the vaccine antigen.,,Jie Zheng,,,,,,,,,,,
VO:0005682,Platycodin D vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,Platycodin D,Platycodin D is a plant-derived vaccine adjuvant that induces Th1/Th17 mixed immune profile.,PMID:35011696,Le Liu,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005683,PLGA nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,PLGA|poly(lactic-co-glycolic acid),PLGA is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:31427012|PMID:25957906,Taiyu Lin|Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005685,PNPS-0.3 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,PNPS-0.3,PNPS-0.3 is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:32553971,Taiyu Lin,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005686,Poly-ϵ-caprolactone and chitosan nanoparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,Poly-ϵ-caprolactone and chitosan nanoparticle|PCL and chitosan NPs,Poly-ϵ-caprolactone/chitosan nanoparticles (NPs) are vaccine adjuvants that enhance the immune response to hepatitis B surface antigen (HBsAg).,PMID:28868964|PMID:29160080,Yuping Zheng,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005687,Polyethyleneimine vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,Polyethyleneimine,Polyethyleneimine is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:35651617,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005688,PolyIC:LC vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,PolyIC:LC,PolyIC:LC is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:33705608,Le Liu,,,Toll-like receptor 3 | antiviral innate immune response receptor RIG-I,Th1-biased immune profile,,,,,,,
VO:0005689,polysorbitol-co-PEI polymer,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,polysorbitol-co-PEI polymer,polysorbitol-co-PEI polymer is a synthetic vaccine adjuvant that induces Th1-biased immune profile.,PMID:33782574,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005690,porous silicon microparticle vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,porous silicon microparticle,A micro- and nanometer-sized particle used as a candidate for cancer vaccine adjuvants.,PMID:25937283,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005691,Propionibacterium acnes vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Propionibacterium acnes|P. acnes|Propionibacterium acnes(P. acnes),A bacterium known for its adjuvant effects in experimental and clinical settings.,PMID:29467764,Yuping Zheng,,,Toll-like receptor 2 | Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005692,pSPreS2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,pSPreS2,pSPreS2 is a microbial derivative vaccine adjuvant that induces Th1 resopnse.,PMID:22240340,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005693,QS-17 and QS-18 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,saponin vaccine adjuvant,QS-17 and18,QS-17 and18 is a saponin vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:30656932,Taiyu Lin,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005694,RALDH2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,RALDH2,The rate-limiting enzyme in retinoic acid (RA) biosynthesis.,PMID:27670072,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005695,retinoic acid and IL-15 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,retinoic acid and IL-15,retinoic acid and IL-15 is a combination vaccine adjuvant that induces mixed Th1/Th17 response.,PMID:21307853,Josh Monickaraj,,,,Th1/Th17 mixed immune profile,,,,,,,
VO:0005696,rHP-NAP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,rHP-NAP,rHP-NAP is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:32224538,Taiyu Lin,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005697,RNadjuvant vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,RNadjuvant,"A 547-nt uncapped noncoding ssRNA containing polyU repeats, stabilized by a cationic carrier peptide.",PMID:28077601,Yuping Zheng,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005698,rNDV-mOX40L vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,rNDV-mOX40L,rNDV-mOX40L is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.,PMID:34602608,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005699,Rotavirus VP6 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Rotavirus VP6,Rotavirus VP6 is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:31083495,Taiyu Lin,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005700,Rv3628 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Rv3628,Rv3628 is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.,PMID:34786473,Le Liu,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005701,SAG1 and TLR-5 ligand vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,SAG1 and TLR-5 ligand,SAG1 and TLR-5 ligand is a combination vaccine adjuvant Th1-biased immune profile.,PMID:31610951,Taiyu Lin,,,Toll-like receptor 5,Th1-biased immune profile,,,,,,,
VO:0005702,Shrimp anti-lipopolysaccharide factor vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,Shrimp anti-lipopolysaccharide factor,"An antimicrobial peptide known for its anticancer properties, including tumor progression suppression.",PMID:26006716,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005703,solid nanoemulsion vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,solid nanoemulsion,"An anhydrous, highly dispersed vehicle containing active pharmaceutical ingredients like imiquimod in a submicron particle size distribution, carried in a suspended state.",PMID:27318760,Yuping Zheng,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005704,solid-in-oil-in-water emulsion vaccine adjuvant,vaccine adjuvant,AdjuvareDB,emulsion vaccine adjuvant,solid-in-oil-in-water emulsion,solid-in-oil-in-water emulsion is a emulsion vaccine adjuvant that induces Th1-biased immune profile.,PMID:35093824,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005705,sPD-1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,sPD-1,sPD-1 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.,PMID:33019546,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005706,sPLA2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,sPLA2,sPLA2 is a cytokine vaccine adjuvant Th2-biased immune profile.,PMID:32341057,Taiyu Lin,,,,Th2-biased immune profile,,,,,,,
VO:0005707,spontaneous nanoliposome antigen particleization vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,spontaneous nanoliposome antigen particleization,spontaneous nanoliposome antigen particleization is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.,PMID:10515829,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005708,sticholysin II vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,sticholysin II,A pore-forming protein from the Caribbean Sea anemone Stichodactyla helianthus.,PMID:28258198,Yuping Zheng,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005709,synthetic melanin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,synthetic melanin,synthetic melanin is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:32561966,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005710,t-NanoCpG vaccine adjuvant,vaccine adjuvant,AdjuvareDB,CpG DNA vaccine adjuvant,t-NanoCpG,t-NanoCpG is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.,PMID:35253404,Le Liu,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005711,T7-alum vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,T7-alum|Alum-TLR7,Vaccine adjuvant composed of a TLR7 agonist adsorbed to alum.,PMID:26812180|PMID:27439378,Yuping Zheng,,,Toll-like receptor 7,Th1/Th17 mixed immune profile,,,,,,,
VO:0005712,Taishan Robinia Pseudoacacia polysaccharide vaccine adjuvant,vaccine adjuvant,AdjuvareDB,plant-derived vaccine adjuvant,TRPPS|Taishan Robinia Pseudoacacia polysaccharides,Taishan Robinia Pseudoacacia polysaccharide is a polysaccharides derived from the Robinia pseudoacacia flower.,PMID:28935204,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005713,TDM vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,TDM,TDM is a microbial derivative vaccine adjuvant adjuvant that induces Th1 response.,PMID:23602766|PMID:23740922,Josh Monickaraj,,,C-type lectin domain family 4 member E,Th1-biased immune profile,,,,,,,
VO:0005714,TF-Al vaccine adjuvant,vaccine adjuvant,AdjuvareDB,aluminum vaccine adjuvant,TF-Al,Aluminum vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:34960154,Le Liu,,,Toll-like receptor 2,Th1/Th2 mixed immune profile,,,,,,,
VO:0005715,thymosin alpha-1 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,thymosin alpha-1,thymosin alpha-1 is a cytokine vaccine adjuvant Th1-biased immune profile.,PMID:31764244,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005716,TLR agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates Toll-like receptors (TLRs) to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor'),,,,,
VO:0005717,TLR7 agonist and NOD2 agonist vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,TLR7 agonist and NOD2 agonist,TLR7 agonist and NOD2 agonist is a combination vaccine adjuvant Th1-biased immune profile.,PMID:32739871,Taiyu Lin,,,nucleotide-binding oligomerization domain-containing protein 2 | Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005718,TLR7-8 RNA ligands vaccine adjuvant,vaccine adjuvant,AdjuvareDB,oligonucleotide vaccine adjuvant,TLR7-8 RNA ligands,oligonucleotide vaccine adjuvant that induces Th1-biased immune profile,PMID:34315922,Le Liu,,,Toll-like receptor 7 | Toll-like receptor 8,Th1-biased immune profile,,,,,,,
VO:0005719,trichosanthin vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,trichosanthin,trichosanthin is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.,PMID:34900541,Le Liu,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005720,TRIF vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,TRIF,TRIF is a microbial derivative vaccine adjuvant that induces Th1 response.,PMID:20466439|PMID:16775309,Josh Monickaraj,,,Toll-like receptor 3 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005721,Tumour-derived exosome vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,Tumour-derived exosome|TEX|Tumour-derived exosomes (TEXs),"Tumour-derived exosome is an exosomes released by tumour cells, with potential use in cancer vaccines.",PMID:29112686,Yuping Zheng,,,,Th1-biased immune profile,,,,,,,
VO:0005722,U-Omp19 and alum vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,U-Omp19 and alum,U-Omp19 and alum is a combination vaccine adjuvant that induces Th1-biased immune profile.,PMID:35296091,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005723,VISA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,VISA,VISA is a synthetic vaccine adjuvant that induces Th1 response.,PMID:21303708,Josh Monickaraj,,,interferon-induced helicase C domain-containing protein 1,Th1-biased immune profile,,,,,,,
VO:0005724,α-galactosylceramide vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,α-galactosylceramide,α-galactosylceramide is a microbial derivative vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:35095921,Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005725,α-GalCer and MPL vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,α-GalCer and MPL,"α-Galactosylceramide (α-GalCer) is a Natural Killer T Cell Ligand, and Monophosphoryl lipid A (MPL) is a TLR4 ligand.",PMID:26811064,Yuping Zheng,,,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005726,LAB EPS vaccine adjuvant,vaccine adjuvant,AdjuvareDB,microbial derivative vaccine adjuvant,LAB EPS,LAB EPS is a microbial derivative vaccine adjuvant Th1-biased immune profile.,PMID:32512102,Taiyu Lin,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005727,pcIFN-gamma vaccine adjuvant,vaccine adjuvant,AdjuvareDB,IFN-gamma vaccine adjuvant,pcIFN-gamma,IFN-gamma vaccine adjuvant that induces Th1 response,PMID:11780322|PMID:11544460|PMID:34081944,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005728,rcIL-15 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,rcIL-15,rcIL-15 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.,PMID:34103211,Le Liu,,,,Th1-biased immune profile,,,,,,,
VO:0005729,AAV-IL-27 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,IL-27 vaccine adjuvant,AAV-IL-27,AAV-IL-27 is a cytokine vaccine adjuvant that induces Treg-biased immune profile.,PMID:33294255,Le Liu,,,,Treg-biased immune profile,,,,,,,
VO:0005730,rhIL-7 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,rhIL-7 adjuvant,rhIL-7 adjuvant is a cytokine vaccine adjuvant.,PMID:22550117|PMID:20068111|PMID:15841203,Josh Monickaraj,,,,,,,,,,,
VO:0005731,c-di-AMP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,nucleic acid vaccine adjuvant,c-di-AMP,c-di-AMP is a nucleic acid vaccine adjuvant Th1/Th2 mixed immune profile.,PMID:30838180,Taiyu Lin,,,protein MB21D1,Th1/Th2 mixed immune profile,,,,,,,
VO:0005732,VLP@Silica vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,VLP@Silica,VLP@Silica is a particulate antigen delivery system vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:35763693,Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005733,DP-D vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,DP-D,DP-D is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:32112853,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005734,T7-EA vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,T7-EA,T7-EA is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:32131853,Taiyu Lin,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005735,STING V155M vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,V155M,STING V155M is a synthetic vaccine adjuvant that induces Th1/Th2/Th17 mixed immune profile.,PMID:33677092,Le Liu,,,protein MB21D1,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0005736,LCP vaccine adjuvant,vaccine adjuvant,AdjuvareDB,particulate antigen delivery system vaccine adjuvant,LCP,LCP is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.,PMID:21674338,Le Liu,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005737,TLR3 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR3 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 3,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 3'),,,,,
VO:0005738,Ad-p53 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,adenovirus-mediated vaccine adjuvant,Ad-p53,Ad-p53 is a genetic cancer adjuvant.,PMID:10430074|PMID:9704675|PMID:10629843|PMID:12487055,Josh Monickaraj,,,,,,,,,,,
VO:0005739,Ad-SLC vaccine adjuvant,vaccine adjuvant,AdjuvareDB,cytokine vaccine adjuvant,Ad-SLC,Ad-SLC is a cytokine vaccine adjuvant that induces a Th1 response.,PMID:23229068|PMID:21997231,Josh Monickaraj,,,,Th1-biased immune profile,,,,,,,
VO:0005740,TLR4 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR4 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 4,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 4'),,,,,
VO:0005741,AS15 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,combination vaccine adjuvant,AS15,"Combination vaccine adjuvant contains QS21, MPLA, and CPG7909 that induces Th1/Th2 mixed response.",PMID:30470547|PMID:23715572|PMID:36798121,Taiyu Lin|Josh Monickaraj,,,Toll-like receptor 4 | Toll-like receptor 9,Th1/Th2 mixed immune profile,,,,,,,
VO:0005742,AS1517499 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,AS1517499,AS1517499 is a synthetic vaccine adjuvant Th2-biased immune profile.,PMID:32244885,Taiyu Lin,,,,Th2-biased immune profile,,,,,,,
VO:0005743,TLR5 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR5 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 5,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 5'),,,,,
VO:0005744,TLR6 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR6 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 6,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 6'),,,,,
VO:0005745,TLR7 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR7 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 7,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 7'),,,,,
VO:0005746,L. polysaccharide vaccine adjuvant,vaccine adjuvant,AdjuvareDB,carbohydrate vaccine adjuvant,L. polysaccharide,L. polysaccharide is a carbohydrate vaccine adjuvant that induces Th1/Th2 mixed immune profile.,PMID:35698367,Le Liu,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005747,TLR8 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR8 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 8,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 8'),,,,,
VO:0005748,TLR9 agonist vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant that stimulates TLR9 to enhance the immune response to vaccination.,,Jie Zheng,,,Toll-like receptor 9,,,('vaccine adjuvant' and 'target receptor' some 'Toll-like receptor 9'),,,,,
VO:0005749,NS-TLR vaccine adjuvant,vaccine adjuvant,AdjuvareDB,synthetic vaccine adjuvant,NS-TLR,NS-TLR is a synthetic vaccine adjuvant Th1-biased immune profile.,PMID:31276378,Taiyu Lin,,,,Th1-biased immune profile,,,,,,,
VO:0005750,SBAS2 vaccine adjuvant,vaccine adjuvant,AdjuvareDB,AS02 vaccine adjuvant,SBAS2,AS02 vaccine adjuvant that induces Th1 response,PMID:12576434,Josh Monickaraj,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005751,TFPR1 vaccine adjuvant,vaccine adjuvant,LLM,animal-derived vaccine adjuvant,TFPR1,"Vaccine adjuvant derived from snake venom that activates the innate immune response by binding and engaging Toll-like receptor 2 (TLR2) on immune cells, which leads to the activation of dendritic cells and enhances antigen presentation.",PMID:34960154|PMID:31629567,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 2,Th1-biased immune profile,,,,,,,
VO:0005752,Murabutide vaccine adjuvant,vaccine adjuvant,LLM,peptide vaccine adjuvant,Murabutide,"Murabutide induces an additive effect on immunogenicity when formulated together with Advax, initiating a sequence of events starting with the recognition of murabutide by pattern recognition receptors (PRRs) like TLRs.",PMID:24554695,Josh Monickaraj|Hasin Rehana,,,nucleotide-binding oligomerization domain-containing protein 2,Th1-biased immune profile,,,,,,,
VO:0005753,Ace-DEX vaccine adjuvant,vaccine adjuvant,LLM,particulate antigen delivery system vaccine adjuvant,Ace-DEX,"The Ace-DEX adjuvant triggers an immune response by sensing its presence through pattern recognition receptors (PRRs), such as TLRs.",PMID:30281314,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005754,GDQ vaccine adjuvant,vaccine adjuvant,LLM,TLR agonist vaccine adjuvant,GDQ,"GDQ triggers a strong immune response by initially sensing pathogens through pattern recognition receptors (PRRs), such as TLRs, which leads to the activation of innate immune cells like dendritic cells. ",PMID:26874325,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 7,Th1-biased immune profile,,,,,,,
VO:0005755,NADA vaccine adjuvant,vaccine adjuvant,LLM,oligonucleotide vaccine adjuvant,NADA,"The slow-release synthetic oligodeoxynucleotide (ODN) adjuvant triggers an immune response by initially sensing through pattern recognition receptors (PRRs), such as TLRs, which leads to the activation of innate immune cells like dendritic cells.",PMID:36868876,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0005756,SMQ vaccine adjuvant,vaccine adjuvant,LLM,combination vaccine adjuvant,SMQ,"The SMQ adjuvant triggers an immune response by activating the NLRP3 inflammasome, a multiprotein complex that senses cellular stress and triggers the production of pro-inflammatory cytokines, such as IL-1β.",PMID:37913775,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005757,PHAD vaccine adjuvant,vaccine adjuvant,LLM,TLR agonist vaccine adjuvant,PHAD,"PHAD triggers an innate immune response, activating dendritic cells through a TLR4-mediated signaling cascade.",PMID:34362603,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005758,ST101036 vaccine adjuvant,vaccine adjuvant,LLM,synthetic vaccine adjuvant,ST101036,Vaccine adjuvant activates pattern recognition receptors (PRRs) such as TLRs trigger an innate immune response and leads to the activation of dendritic cells.,PMID:36731641,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005759,MIP-1alpha vaccine adjuvant,vaccine adjuvant,LLM,cytokine vaccine adjuvant,MIP-1alpha,"MIP-1alpha acts as an adjuvant by upregulating the function of antigen-presenting cells (APCs), enhancing their ability to process and present antigens.",PMID:11134269,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005760,Levamisole vaccine adjuvant,vaccine adjuvant,LLM,synthetic vaccine adjuvant,Levamisole,"Levamisole initiates an immune response by stimulating strong Th1 cell activity, which is characterized by the activation of T helper 1 cells.",PMID:15246629,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005761,Hsp65 vaccine adjuvant,vaccine adjuvant,LLM,microbial derivative vaccine adjuvant,Hsp65,"Microbial derivative vaccine adjuvant recognizes TLR4, and senses Hsp65, leading to the activation of innate immune cells like dendritic cells.",PMID:21546794|PMID:28194152|PMID:15809303,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 2 | Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0005762,HVJ-Envelope vaccine adjuvant,vaccine adjuvant,LLM,particulate antigen delivery system vaccine adjuvant,HVJ-Envelope,"Particulate antigen delivery system vaccine adjuvant initiates an immune response by being sensed by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), leading to the activation of innate immune cells, including dendritic cells, which then present antigens to T cells, inducing a Th1 response and the production of interferon-gamma (IFN-γ). ",PMID:21546794,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005763,GPI-0100 vaccine adjuvant,vaccine adjuvant,LLM,saponin vaccine adjuvant,GPI-0100,"Upon recognition by pattern recognition receptors (PRRs) such as TLRs, GPI-0100 initiates an immune response by activating innate immune cells like dendritic cells.",PMID:32101001,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005764,Tween 80 vaccine adjuvant,vaccine adjuvant,LLM,tensoactive compound vaccine adjuvant,Tween 80,"Tween 80 induces a suppressed Th1 response, characterized by decreased T cell activation and cytokine production, resulting in a reduced adaptive immune response.",PMID:15246629,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005765,EP67 vaccine adjuvant,vaccine adjuvant,LLM,peptide vaccine adjuvant,EP67,"The EP67 adjuvant induces an inflammatory immune response by triggering the release of Th1-type cytokines from APCs, which are activated through the C5a receptor.",PMID:19836478,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005766,1Z105 vaccine adjuvant,vaccine adjuvant,LLM,TLR agonist vaccine adjuvant,1Z105,"The adjuvant induces rapid Th2-associated IgG1 responses by initially sensing pathogens through pattern recognition receptors (PRRs) like TLRs, leading to innate cell activation of dendritic cells, and subsequently shaping the adaptive response through T cell polarization towards Th2 cells, resulting in the production of IgG1 antibodies.",PMID:25568203,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 4,Th2-biased immune profile,,,,,,,
VO:0005767,Curdlan vaccine adjuvant,vaccine adjuvant,LLM,microbial derivative vaccine adjuvant,Curdlan,"Upon sensing by Dectin-1, Curdlan triggers an innate immune response, activating dendritic cells that subsequently induce the activation of T follicular helper (TFH) cells, germinal centers (GCs), and bone marrow high-affinity plasma cells. This leads to the production of high-affinity antibodies.",PMID:29541075,Josh Monickaraj|Hasin Rehana,,,C-type lectin domain family 7 member A,Th1-biased immune profile,,,,,,,
VO:0005768,CARP-1 vaccine adjuvant,vaccine adjuvant,LLM,plant-derived vaccine adjuvant,CARP-1,"The adjuvant CARP-1 initiates an immune response by stimulating the CD40 and CD86 co-receptors on antigen-presenting cells, leading to the production of pro-inflammatory cytokines such as TNF-α and IL-6. This activation of the NF-κB and MAPK signaling pathways ultimately shapes the adaptive immune response, including T cell polarization and antibody production.",PMID:35698367,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005769,ASPPR vaccine adjuvant,vaccine adjuvant,LLM,microbial derivative vaccine adjuvant,ASPPR,"Upon sensing the ASPPR adjuvant, innate immune cells express pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), which lead to the activation of antigen-processing cells (APCs) like dendritic cells.",PMID:25736195,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 2 | Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0005770,BLP vaccine adjuvant,vaccine adjuvant,LLM,particulate antigen delivery system vaccine adjuvant,BLP,"BLP adjuvant enhances immune responses by boosting both systemic and mucosal immunity, initiating a cascade of events starting with the recognition of pathogens by pattern recognition receptors (PRRs), such as TLRs. This recognition triggers the activation of innate immune cells like dendritic cells, which subsequently polarize T cells and induce antibody production.",PMID:30312742|PMID:24598720,Josh Monickaraj|Hasin Rehana,,,Toll-like receptor 2,Th1/Th17 mixed immune profile,,,,,,,
VO:0005771,BX795 vaccine adjuvant,vaccine adjuvant,LLM,synthetic vaccine adjuvant,BX795,"BX795 adjuvant interferes with antiviral signaling by inhibiting TANK-binding kinase 1 (TBK1), thereby enhancing the replication of replication-competent live viral vaccines. This inhibition of TBK1 prevents the activation of interferon (IFN) responses, creating an environment that favors viral replication.",PMID:32574095,Josh Monickaraj|Hasin Rehana,,,,,,,,,,,
VO:0005772,C5a vaccine adjuvant,vaccine adjuvant,LLM,peptide vaccine adjuvant,C5a,"C5a activates the NLRP3 inflammasome, initiating a cascade of events that ultimately leads to the formation of a depot for slow antigen release. This process triggers the activation of innate immune cells, including neutrophils and macrophages, which release pro-inflammatory cytokines such as IL-1β.",PMID:10799917,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005773,HP-β-CD vaccine adjuvant,vaccine adjuvant,LLM,carbohydrate vaccine adjuvant,HP-β-CD,"The adjuvant HP-β-CD temporarily releases IL-33 from alveolar epithelial type 2 cells in the lung, initiating an immune response through IL-33/ST2 signaling. This release of IL-33 subsequently activates innate immune cells, including dendritic cells, which then shape the adaptive response by presenting antigens to T cells, leading to T cell polarization and antibody production.",PMID:32210964,Josh Monickaraj|Hasin Rehana,,,,Th1/Th2 mixed immune profile,,,,,,,
VO:0005774,CYT387 vaccine adjuvant,vaccine adjuvant,LLM,synthetic vaccine adjuvant,CYT387,"CYT387 interferes with antiviral signaling by inhibiting TANK-binding kinase 1 (TBK1), which enhances the replication of replication-competent live viral vaccines. This inhibition of TBK1 leads to the suppression of type I interferon (IFN) signaling, which in turn allows for the replication of viral vaccines.",PMID:32574095,Josh Monickaraj|Hasin Rehana,,,,,,,,,,,
VO:0005775,CARP-2 vaccine adjuvant,vaccine adjuvant,LLM,plant-derived vaccine adjuvant,CARP-2,"CARP-2 stimulates the immune response by binding to CD40 and CD86, triggering the activation of NF-κB and MAPK pathways. This activation leads to the production of pro-inflammatory cytokines, including TNF-α and IL-6, which in turn activate dendritic cells and other innate immune cells, ultimately shaping the adaptive response. The production of TNF-α and IL-6 also promotes the activation of T cells, leading to the polarization of T cells towards Th1 and Th17 responses, while also inducing antibody production.",PMID:35698367,Josh Monickaraj|Hasin Rehana,,,,Th1-biased immune profile,,,,,,,
VO:0005776,peptide vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant composed of peptides that is added to vaccines to enhance the body’s immune response to an antigen.,,Jie Zheng,,,,,,,,,,,
VO:0005777,animal-derived vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,"Vaccine adjuvant obtained from animals, such as from animal tissues, fluids, or byproducts and added to vaccines to enhance the body's immune response to an antigen.",,Jie Zheng,,,,,,,,,,,
VO:0005778,fusion protein vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,"Vaccine adjuvant composed of fusion proteins, which is added to vaccines to enhance and modulate the immune response to a specific antigen.",,Jie Zheng,,,,,,,,,,,
VO:0005779,adenovirus-mediated vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,Vaccine adjuvant composed of adenovirus to stimulate and augment the immune response to an antigen.,,Jie Zheng,,,,,,,,,,,
VO:0006092,LMQ vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,LMQ,A combination vaccine adjuvant that is liposome-based adjuvant of a synthetic TLR agonist and saponin induced a Th1-biased immune response.,https://www.ncbi.nlm.nih.gov/pubmed/?term=36634821|https://www.ncbi.nlm.nih.gov/pubmed/?term=36119058|https://www.ncbi.nlm.nih.gov/pubmed/?term=37029167,Maria Lawrenz|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature: Combination adjuvant
Mechanism of Action: n/a
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Maria Lawrenz, Vaccine Formulation Institute",https://github.com/vaccineontology/VO/issues/614,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0006093,CPDI-02 vaccine adjuvant,vaccine adjuvant,VAC,peptide vaccine adjuvant,CPDI-02,A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils.,https://www.ncbi.nlm.nih.gov/pubmed/?term=11710544|https://www.ncbi.nlm.nih.gov/pubmed/?term=19836478|https://www.ncbi.nlm.nih.gov/pubmed/?term=20965299,Joseph Vetro|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature: Other - Peptide
Mechanism of Action: (Primary) Selectively activates C5aR1 on mononuclear phagocytes vs neutrophils
Immune profile induced: Th1/Th2/Th17
Route of immunization: IP, IV
Point of Contact: Joseph Vetro, University of Nebraska Medical Center",https://github.com/vaccineontology/VO/issues/615,,Th1/Th2/Th17 mixed immune profile,,,,,,,
VO:0006094,CpG55.2 vaccine adjuvant,vaccine adjuvant,VAC,CpG DNA vaccine adjuvant,CpG55.2,A vaccine adjuvant with a Toll-like receptor 9 (TLR9)-active oligonucleotide that is able to induce Th1/Th2 immune responses.,https://www.ncbi.nlm.nih.gov/pubmed/?term=34420786|https://www.ncbi.nlm.nih.gov/pubmed/?term=34399628|https://www.ncbi.nlm.nih.gov/pubmed/?term=34456075|https://www.ncbi.nlm.nih.gov/pubmed/?term=34420786|https://www.ncbi.nlm.nih.gov/pubmed/?term=24554695|https://www.ncbi.nlm.nih.gov/pubmed/?term=32418798|https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809|https://www.ncbi.nlm.nih.gov/pubmed/?term=33479242|https://www.ncbi.nlm.nih.gov/pubmed/?term=27387453,Nikolai Petrovsky|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature: Nucleic acid
Mechanism of Action: TLR9 agonist
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM, SQ
Point of Contact: Nikolai Petrovsky, Vaxine LTD
",https://github.com/vaccineontology/VO/issues/616,Toll-like receptor 9,Th1/Th2 mixed immune profile,,,,,,,
VO:0006095,SMNP vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,SMNP|saponin and MPLA nanoparticle vaccine adjuvant|saponin and MPLA nanoparticles,"A combination vaccine adjuvant that includes AS01-mimic, Immune Stimulating Complex (ISCOM) with a TLR4 agonist.",PMID:34860581,Katarzyna Kaczmarek Michaels|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar|Le Liu,"Chemical Nature: Combination adjuvant
Mechanism of Action: Cytokine induction in draining lymph nodes with increased lymph flow and lymph antigen accumulation
Immune profile induced: Mixed Th1/Th2
Route of immunization: s.c. / i.m. / i.n.
Point of Contact: Katarzyna Kaczmarek Michaels, Massachusetts Institute of Technology
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=34860581
https://www.ncbi.nlm.nih.gov/pubmed/?term=36131022
https://www.ncbi.nlm.nih.gov/pubmed/?term=34878851",https://github.com/vaccineontology/VO/issues/632,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0006096,ALFQ vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,ALFQ,"A combination vaccine adjuvant that is an AS01-mimic, liposomal adjuvant of a TLR4 agonist and saponin.",,Mangala Rao|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature:
- Natural compound
- Synthetic derivative of natural compound
- Combination adjuvant
Mechanism of Action: MPLA: TLR4 agonist QS21: Sugar-lawn likely recog. by lectins to facilitate uptake by M_, DCs, etc
Immune profile induced: Mixed Th1/Th2
Route of immunization: ID, IM
Point of Contact: Mangala Rao, Walter Reed Army Institute of Research
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178
https://www.ncbi.nlm.nih.gov/pubmed/?term=31827000
https://www.ncbi.nlm.nih.gov/pubmed/?term=34470866
https://www.ncbi.nlm.nih.gov/pubmed/?term=35632473
https://www.ncbi.nlm.nih.gov/pubmed/?term=36417525
https://www.ncbi.nlm.nih.gov/pubmed/?term=34914540
https://www.ncbi.nlm.nih.gov/pubmed/?term=32881968
https://www.ncbi.nlm.nih.gov/pubmed/?term=26372857
https://www.ncbi.nlm.nih.gov/pubmed/?term=36055874
https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178
https://www.ncbi.nlm.nih.gov/pubmed/?term=36679887
https://www.ncbi.nlm.nih.gov/pubmed/?term=36934088
https://www.ncbi.nlm.nih.gov/pubmed/?term=34903722
https://www.ncbi.nlm.nih.gov/pubmed/?term=31775762
https://www.ncbi.nlm.nih.gov/pubmed/?term=28596090
https://www.ncbi.nlm.nih.gov/pubmed/?term=31151801
https://www.ncbi.nlm.nih.gov/pubmed/?term=34711815
https://www.ncbi.nlm.nih.gov/pubmed/?term=34159328
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04268420
https://clinicaltrials.gov/ct2/show/NCT04296279
https://clinicaltrials.gov/ct2/show/NCT04784767
https://clinicaltrials.gov/ct2/show/NCT05500417
https://clinicaltrials.gov/ct2/show/NCT04826094
https://clinicaltrials.gov/ct2/show/NCT04658667
https://clinicaltrials.gov/ct2/show/NCT05423418",https://github.com/vaccineontology/VO/issues/633,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0006097,2G023A vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,2G023A,A vaccine adjuvant which is a small molecule TLR agonist that drives a mixed Th1/Th2 response.,,Dennis Carson|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature:
Small molecule
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM
Point of Contact: Dennis Carson, UCSD",https://github.com/vaccineontology/VO/issues/648,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0006098,2G053 vaccine adjuvant,vaccine adjuvant,VAC,TLR agonist vaccine adjuvant,2G053,"A vaccine adjuvant, a small molecule TLR agonist that drives a mixed Th1/Th2 response.",,Dennis Carson|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature:
Small molecule
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM
Point of Contact: Dennis Carson, UCSD",https://github.com/vaccineontology/VO/issues/649,Toll-like receptor 4,Th1/Th2 mixed immune profile,,,,,,,
VO:0006099,GLA-Alum vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,GLA-Alum,A combination vaccine adjuvant of a synthetic TLR agonist and aluminum salt.,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature:
- Synthetic derivative of natural compound
- Combination adjuvant
- Mineral salt
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased
Route of immunization: SQ, IM
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=37454145
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=28828575
https://www.ncbi.nlm.nih.gov/pubmed/?term=30013570
https://www.ncbi.nlm.nih.gov/pubmed/?term=24211167
https://www.ncbi.nlm.nih.gov/pubmed/?term=23933525
https://www.ncbi.nlm.nih.gov/pubmed/?term=34597297
https://www.ncbi.nlm.nih.gov/pubmed/?term=36996185
https://www.ncbi.nlm.nih.gov/pubmed/?term=28464026
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03910972
https://clinicaltrials.gov/ct2/show/NCT02126462
https://clinicaltrials.gov/ct2/show/NCT02839161
https://clinicaltrials.gov/ct2/show/NCT03110757
https://clinicaltrials.gov/ct2/show/NCT02337855
https://clinicaltrials.gov/ct2/show/NCT01717950
https://clinicaltrials.gov/ct2/show/NCT02476773
https://clinicaltrials.gov/ct2/show/NCT01261130
https://clinicaltrials.gov/ct2/show/NCT01385189
https://clinicaltrials.gov/ct2/show/NCT03172975",https://github.com/vaccineontology/VO/issues/650,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0006100,SLA-Alum vaccine adjuvant,vaccine adjuvant,VAC,combination vaccine adjuvant,SLA-Alum,A combination vaccine adjuvant of a synthetic TLR4 agonist and aluminum salt.,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature:
- Synthetic derivative of natural compound
- Combination adjuvant
- Mineral salt
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=26901122
https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577",https://github.com/vaccineontology/VO/issues/651,Toll-like receptor 4,Th1-biased immune profile,,,,,,,
VO:0006101,Stable Emulsion (SE) vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,Stable Emulsion (SE),An emulsion vaccine adjuvant that includes squalene-based oil-in-water emulsion.,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,"Chemical Nature: Emulsion
Mechanism of Action: n/a
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM, SQ
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214
https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687
https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728
https://www.ncbi.nlm.nih.gov/pubmed/?term=37495191
https://www.ncbi.nlm.nih.gov/pubmed/?term=36256646
https://www.ncbi.nlm.nih.gov/pubmed/?term=28089141
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03330899
https://clinicaltrials.gov/ct2/show/NCT01612000
https://clinicaltrials.gov/ct2/show/NCT02464163
https://clinicaltrials.gov/ct2/show/NCT02464163",https://github.com/vaccineontology/VO/issues/652,,Th1/Th2 mixed immune profile,,,,,,,
VO:0006102,oligonucleotide vaccine adjuvant,vaccine adjuvant,category,nucleic acid vaccine adjuvant,,A nucleic acid vaccine adjuvant that is primarily composed of oligonucleotide.,,Jie Zheng,,,,,,,,,,,
VO:0006103,A-910823 vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,A-910823,"An emulsion vaccine adjuvant that is squalene-based adjuvant, induces T follicular helper cells and humoral immune responses via alpha-tocopherol component.",PMID:36891311,Nilufer kosar|Maki Hayase|Jie Zheng,"Chemical Nature: Emulsion
Mechanism of Action: n/a
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Maki Hayase, Shionogi &Co., Ltd

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36372670
https://www.ncbi.nlm.nih.gov/pubmed/?term=36891311
https://www.ncbi.nlm.nih.gov/pubmed/?term=36460696
https://www.ncbi.nlm.nih.gov/pubmed/?term=35691872

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT05212948",https://github.com/vaccineontology/VO/issues/666,,Th1-biased immune profile,,,,,,,
VO:0006104,S-540956 vaccine adjuvant,vaccine adjuvant,VAC,oligonucleotide vaccine adjuvant,S-540956,"An oligonucleotide vaccine adjuvant that is a TLR9-agonistic adjuant containing a CpG oligonucleotide annealed to a complementary strand with an amphiphilic chain unit, acts as a potent cancer vaccine adjuvant by targeting draining lymph nodes.",PMID:35003132|PMID:37243234,Nilufer kosar|Maki Hayase|Jie Zheng,"Chemical Nature: Oligonucleotide
Mechanism of Action: Activation of TLR9 signaling pathway
Immune profile induced: Th1-biased

Route of immunization: IM, SQ
Point of Contact: Maki Hayase, Shionogi &Co., Ltd

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=35003132
https://www.ncbi.nlm.nih.gov/pubmed/?term=37243234

Ongoing clinical trials:
N/A",https://github.com/vaccineontology/VO/issues/667,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0006105,precision vaccines program-057 vaccine adjuvant,vaccine adjuvant,VAC,synthetic vaccine adjuvant,Precision Vaccines Program (PVP)-057,A vaccine adjuvant which is a small molecule adjuvant that is able to induce a mixed Th1/Th2 response and active innate immunity. ,,Nilufer kosar|Jie Zheng|Ofer Levy,"It may actually be the world’s first small-molecule TLR3 agonist.|Chemical Nature: Small molecule
Mechanism of Action: Activation of innate immunity
Immune profile induced: Mixed Th1/Th2

Route of immunization: IM, ID
Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital",https://github.com/vaccineontology/VO/issues/676,Toll-like receptor 3,Th1/Th2 mixed immune profile,,,,,,,
VO:0006106,ACM-CpG vaccine adjuvant,vaccine adjuvant,VAC,emulsion vaccine adjuvant,ACM-CpG,An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature.,,Nilufer kosar|Jie Zheng|Madhavan Nallani,"Chemical Nature: Nucleic acid, Emulsion
Mechanism of Action: Innate Immune Activation, preferential uptake by APCs
Immune profile induced: Th1-biased
Definition: TLR-agonist for target; nucleic acid-based adjuvant for chemical nature

Route of immunization: SQ, IN, IM
Point of Contact: Madhavan Nallani, ACM Biolabs

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=34618423
https://www.ncbi.nlm.nih.gov/pubmed/?term=36223228

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT05385991",https://github.com/vaccineontology/VO/issues/690,Toll-like receptor 9,Th1-biased immune profile,,,,,,,
VO:0006107,cowpea mosaic virus vaccine adjuvant,vaccine adjuvant,VAC,particulate antigen delivery system vaccine adjuvant,Cowpea mosaic virus,A particulate antigen delivery system vaccine adjuvant derived from Cowpea mosaic virus that is able to induce a Th1-biased response.,Pubmed:26689376|Pubmed:37844250,Nilufer kosar|Jie Zheng|Nicole Steinmetz|Wolfgang Leitner,"Chemical Nature: Nucleoprotein complex
Mechanism of Action: recognized by PRRs
Immune profile induced: Th1-biased

Route of immunization: Intratumoral, intraperitoneally , IV
Point of Contact: Nicole Steinmetz, University of California, San Diego

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=26689376
https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/684,Toll-like receptor 2 | Toll-like receptor 4 | Toll-like receptor 7,Th1-biased immune profile,NCBITaxon:12264,,,,,,
VO:0006108,nexavant vaccine adjuvant,vaccine adjuvant,VAC,nucleic acid vaccine adjuvant,Nexavant,A nucleic acid vaccine adjuvant that targets on TLR3 agonist to induce a mixed Th1/Th2 response.,Pubmed:36761735|Pubmed:38136298,Nilufer kosar|Jie Zheng|Seungbin Cha,"Chemical Nature: dsRNA
Mechanism of Action: TLR3 agonist
Immune profile induced: Mixed Th1/Th2
category: nucleic-acid based adjuvant (TLR-agonist)
synthetic derivative of natural compound
Route of immunization: IM
Point of Contact: Seungbin Cha, NA Vaccine Institute

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36761735
https://www.ncbi.nlm.nih.gov/pubmed/?term=38136298

Ongoing clinical trials:
none",https://github.com/vaccineontology/VO/issues/694,Toll-like receptor 3,Th1/Th2 mixed immune profile,,,,,,,
VO:0006109,nucleic acid vaccine adjuvant,vaccine adjuvant,category,vaccine adjuvant,,A vaccine adjuvant that is primarily composed of nucleic acid.,,Jie Zheng,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,